Guiding nucleic acids targeting MECP2 and uses thereof

The specific cleavage on MECP2 mRNA through the CRISPR-CAS13 system solved the problem of poor treatment effect of MECP2 related diseases in the prior art, achieved a significant reduction in MECP2 mRNA level and improved disease phenotype, and provided MECP2 related diseases with a significant increase in MECP2 related diseases. A gene therapy tool.

CN119095961APending Publication Date: 2024-12-06HUIGENE THERAPEUTICS CO LTD +2

Patent Information

Application Number
CN202380031024.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-28
Filing Date
2023-03-28
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing methods for treating MECP2-related diseases such as MECP2 repeat syndrome are limited in efficacy, and there is a lack of effective tools to reduce MECP2 gene expression, making it difficult to significantly improve the disease phenotype.

Method used

Using the CRISPR-CAS13 system, the target MECP2 mRNA is specifically cleaved and degraded by designing guide nucleic acids and nucleic acid programmable RNA nuclease (napRNAn), thereby downregulating the expression of the MECP2 gene. The system includes guided nucleic acid, napRNAn and recombinant adeno-associated virus (rAAV) vector genomes for delivery to target cells to achieve degradation of MECP2 mRNA.

Benefits of technology

Significantly lowered MECP2 mRNA levels, improved the disease phenotype in mouse models, and provided a potential gene therapy tool for the treatment of MECP2-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005062919930000261
    Figure BDA0005062919930000261
  • Figure BDA0005062919930000262
    Figure BDA0005062919930000262
  • Figure BDA0005062919930000271
    Figure BDA0005062919930000271
Patent Text Reader

Abstract

The present disclosure provides guide nucleic acids targeting human MECP2mRNA, systems or compositions or rAAV vector genomes comprising the guide nucleic acids, and methods of using the systems or compositions or rAAV vector genomes to treat diseases and disorders associated with human MECP2mRNA.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of and priority to PCT patent application No. PCT / CN2022 / 083477, filed on March 28, 2022, entitled “CRISPR-CAS13 SYSTEM FOR TREATINGMECP2-ASSOCIATEDDISEASES,” which is incorporated herein by reference in its entirety (including any sequence listing and drawings).

[0003] References to electronic sequence listings

[0004] The present disclosure contains an electronic sequence listing ("xxx.xml", created on XX by "WIPOSequence" software according to WIPO Standard ST.26), which is incorporated herein by reference in its entirety. Where the sequence is an RNA sequence, T in the sequence should be considered as U. Background Art

[0005] MECP2 duplication syndrome (MDS) is a devastating childhood neurodevelopmental disorder caused by duplications in the gene encoding methyl-CpG binding protein 2 (MeCP2).

[0006] Citation or identification of any document in this disclosure is not an admission that such document is available as prior art to the present disclosure. Summary of the Invention

[0007] Against the above background, the present disclosure provides certain advantages over the prior art. Although the disclosure herein is not limited to specific advantages, in one aspect, the present disclosure provides a guide nucleic acid comprising:

[0008] (1) a scaffold sequence capable of forming a complex with a nucleic acid programmable RNA nuclease (napRNAn), and

[0009] (2) A guide sequence capable of hybridizing to a target sequence of human MECP2 mRNA to guide the complex to the human MECP2 mRNA.

[0010] In another aspect, the present disclosure provides a system or composition comprising:

[0011] (1) a guide nucleic acid or a polynucleotide encoding the guide nucleic acid, the guide nucleic acid comprising:

[0012] (a) a scaffold sequence capable of forming a complex with a nucleic acid programmable RNA nuclease (napRNAn), and

[0013] (b) a guide sequence capable of hybridizing to a target sequence of human MECP2 mRNA to guide the complex to the human MECP2 mRNA; and

[0014] (2) The napRNAn or a polynucleotide encoding the napRNAn.

[0015] In yet another aspect, the present disclosure provides a recombinant adeno-associated virus (rAAV) vector genome, the rAAV vector genome comprising:

[0016] (a) a first polynucleotide sequence comprising a first sequence encoding a first guide nucleic acid comprising:

[0017] (1) a scaffold sequence capable of forming a complex with a nucleic acid programmable RNA nuclease (napRNAn), and

[0018] (2) a first guide sequence capable of hybridizing to a first target sequence of human MECP2 mRNA to guide the complex to the first guide sequence of the human MECP2 mRNA; and

[0019] (b) a second polynucleotide sequence comprising a sequence encoding the napRNAn,

[0020] The rAAV vector genome is suitable for encapsulation into recombinant AAV particles.

[0021] In yet another aspect, the present disclosure provides a recombinant AAV (rAAV) particle comprising the rAAV vector genome of the present disclosure.

[0022] In yet another aspect, the present disclosure provides a pharmaceutical composition comprising a system or composition of the present disclosure or an rAAV particle of the present disclosure, and a pharmaceutically acceptable excipient.

[0023] In yet another aspect, the present disclosure provides a method for preventing or treating a disease or disorder associated with human MECP2 mRNA in a subject in need thereof, the method comprising administering to the subject a system or composition of the present disclosure, an rAAV particle of the present disclosure, or a pharmaceutical composition of the present disclosure, wherein the napRNAn modifies the human MECP2 mRNA, and wherein the modification of the human MECP2 mRNA treats the disease or disorder.

[0024] The details of one or more embodiments of the present disclosure are set forth in the following description. Other features or advantages of the present disclosure should be clear from the following drawings and detailed description of several embodiments and from the claims. It should be understood that, unless otherwise indicated, any aspect or embodiment of the present disclosure can be combined with any other aspect or embodiment of the present disclosure to constitute another embodiment disclosed herein, either explicitly or implicitly.

[0025] definition

[0026] The present disclosure will describe specific embodiments, but the present disclosure is not limited thereto and is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present disclosure belongs. Unless otherwise indicated, the terms described below are generally understood to have their ordinary meanings.

[0027] Overview

[0028] Nucleic acid programmable RNA nuclease (napRNAn), such as Cas13, is capable of cutting target RNA under the guidance of a guide nucleic acid (e.g., guide RNA) comprising a guide sequence targeting the target RNA. In some embodiments, the target RNA is eukaryotic.

[0029] Without wishing to be bound by theory, in some embodiments, the guide nucleic acid comprises a scaffold sequence responsible for forming a complex with the napRNAn, and a guide sequence intentionally designed to hybridize with a target sequence of the target RNA, thereby directing the complex comprising the napRNAn and the guide nucleic acid to the target RNA.

[0030] refer to Figure 10 , exemplary dsRNA is described as comprising a 5' to 3' single DNA strand and a 3' to 5' single DNA strand. According to conventional transcription processes, exemplary RNA transcripts can be transcribed using the 3' to 5' single DNA strand as a synthesis template, and thus the 3' to 5' single DNA strand is referred to as the "template strand" or "antisense strand." The RNA transcript so transcribed has the same primary sequence as the 5' to 3' single DNA strand (except that T is replaced by U), and thus the 5' to 3' single DNA strand is referred to as the "coding strand" or "sense strand."

[0031] Exemplary guide nucleic acids are described as comprising a guide sequence and a scaffold sequence. The guide sequence is designed to hybridize with a portion of the RNA transcript (target RNA), and the guide sequence is therefore "targeted" to that portion. Thus, the portion of the target RNA upon which the guide sequence is designed and to which the guide sequence can hybridize is referred to as the "target sequence." In some embodiments, the guide sequence is 100% (perfectly) reverse complementary to the target sequence. In some other embodiments, the guide sequence is reverse complementary to the target sequence and contains mismatches (e.g., Figure 11 exemplified in ).

[0032] Typically, the double-stranded sequence of dsDNA can be represented by the sequence of its 5' to 3' individual DNA strands and, conventionally, written in a 5' to 3' direction / orientation. Typically, nucleic acid sequences (e.g., DNA sequences, RNA sequences) are written in a 5' to 3' direction / orientation.

[0033] For example, for a dsDNA having a 5' to 3' single DNA strand of 5'-ATGC-3' and a 3' to 5' single DNA strand of 3'-TACG-5', the dsDNA can be simply represented as 5'-ATGC-3'. Normally, the RNA transcript (target RNA) transcribed from the dsDNA has a sequence of 5'-AUGC-3'.

[0034] In order to hybridize with the target RNA, in one embodiment, the guide sequence of the guide nucleic acid is designed to have a 5'-GCAU-3' sequence that is completely reverse complementary to the target RNA. According to WIPO's electronic sequence listing standard ST.26, the symbol "t" is used to represent both T in DNA and U in RNA (see "Table 1: List of Nucleotide Symbols", the definition of the symbol "t" is "thymine in DNA / uracil in RNA (t / u)"). Therefore, in the sequence listing according to ST.26, such a guide sequence will be shown as GCAT, but marked as an RNA sequence.

[0035] the term

[0036] As used herein, if a DNA sequence, e.g., 5'-ATGC-3', is transcribed into an RNA sequence (e.g., 5'-AUGC-3') in which each dT (deoxythymidine, or simply "T") in the primary sequence is replaced with U (uridine), and the other dA (deoxyadenosine, or simply "A"), dG (deoxyguanosine, or simply "G"), and dC (deoxycytidine, or simply "C") are replaced with A (adenosine), G (guanosine), and C (cytidine), respectively, it is said in the present disclosure that the DNA sequence "encodes" the RNA sequence.

[0037] As used herein, the term "activity" refers to biological activity. In some embodiments, the activity includes enzymatic activity, such as the catalytic ability of the effector. For example, the activity can include nuclease activity, such as RNA nuclease activity, RNA endonuclease activity.

[0038] As used herein, the term "complex" refers to a grouping of two or more molecules. In some embodiments, the complex comprises polypeptides and nucleic acids that interact with each other (e.g., bind, contact, adhere). As used herein, the term "complex" may refer to a grouping of guide nucleic acids and polypeptides (e.g., napRNAn, such as Cas13 polypeptides). As used herein, the term "complex" may refer to a grouping of guide nucleic acids, polypeptides, and target sequences. As used herein, the term "complex" may refer to a grouping of guide nucleic acids, napRNAn, and optionally target RNAs targeting a target RNA.

[0039] As used herein, the term "guide nucleic acid" refers to any nucleic acid that helps target napRNAn (e.g., Cas13 polypeptide) to a target sequence (e.g., a sequence of a target RNA). The guide nucleic acid can be designed to include a sequence complementary to a specific nucleic acid sequence (e.g., a sequence of a target RNA). The guide nucleic acid can include a scaffold sequence that helps guide napRNAn to the target RNA. In some embodiments, the guide nucleic acid is a guide RNA.

[0040] As used herein, the terms "nucleic acid," "polynucleotide," and "nucleotide sequence" are used interchangeably to refer to a polymeric form of nucleotides of any length, including deoxyribonucleotides, ribonucleotides, combinations thereof, and analogs or modifications thereof.

[0041] As used in the context of CRISPR-Cas technology (e.g., CRISPR-Cas13 technology), the term "guide RNA" is used interchangeably with the term "CRISPR RNA (crRNA)", "single guide RNA (sgRNA)" or "RNA guide", the term "guide sequence" is used interchangeably with the term "spacer sequence", and the term "scaffold sequence" is used interchangeably with the term "direct repeat sequence".

[0042] As described herein, guide sequences are designed to hybridize with target sequences. As used herein, the term "hybridize (hybridize, hybridizing or hybridization)" refers to a reaction in which one or more polynucleotide sequences react to form a complex, which is stabilized via hydrogen bonds between the bases of the polynucleotide sequences. Hydrogen bonds can occur by Watson Crick base pairing, Hoogstein binding or in any other sequence-specific manner. The polynucleotide sequence capable of hybridizing with a given polynucleotide sequence is referred to as the "complementary sequence" of a given polynucleotide sequence. As used herein, the hybridization of a guide sequence and a target sequence is so stable that the functional domain associated with (e.g., fusion) of an effector polypeptide (e.g., napRNAn) or the effector polypeptide compounded with the nucleic acid comprising the guide sequence acts (e.g., cleavage, deamination) on the target sequence or its complementary sequence (e.g., the sequence of the target RNA or its complementary sequence).

[0043] For the purpose of hybridization, in some embodiments, the guide sequence is complementary or reverse complementary to the target sequence. As used herein, the term "complementary" refers to the ability of the core bases of a first polynucleotide sequence (such as a guide sequence) to base pair with the core bases of a second polynucleotide sequence (such as a target sequence) by traditional Watson Crick base pairing. Two complementary polynucleotide sequences can be non-covalently bound under appropriate temperature and solution ionic strength conditions. In some embodiments, the first polynucleotide sequence (e.g., a guide sequence) has 100% (complete) complementarity with the second nucleic acid (e.g., a target sequence). In some embodiments, if the first polynucleotide sequence (e.g., a guide sequence) has at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% complementarity with the second polynucleotide sequence (e.g., a target sequence), the first polynucleotide sequence is complementary to the second nucleic acid. As used herein, the term "substantially complementary" refers to a polynucleotide sequence (e.g., a guide sequence) having a certain degree of complementarity with a second polynucleotide sequence (e.g., a target sequence). In some embodiments, the level of complementarity enables a first polynucleotide sequence (e.g., a guide sequence) to hybridize with a second polynucleotide sequence (e.g., a target sequence) with sufficient affinity to allow an effector polypeptide (e.g., napRNAn) complexed with the first polynucleotide sequence or a nucleic acid comprising the first polynucleotide sequence, or a functional domain associated with (e.g., fused to) the effector polypeptide to act (e.g., cleavage, deamination) on the target sequence or its complementary sequence (e.g., the sequence of a target RNA or its complementary sequence). In some embodiments, a guide sequence that is substantially complementary to a target sequence has less than 100% complementarity with the target sequence. In some embodiments, a guide sequence that is substantially complementary to a target sequence is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% complementary to the target sequence.

[0044] As used herein, the term "sequence identity" is related to sequence homology. Homology comparisons can be made by eye, or more usually with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate the percent (%) homology between two or more sequences, and can also calculate the sequence identity shared by two or more amino acid or nucleic acid sequences.

[0045] Sequence homology can be generated by any of a variety of computer programs known in the art, such as BLAST or FASTA etc. The suitable computer program for performing such comparison is GCG Wisconsin Bestfit package (University of Wisconsin, USA; Devereux et al., 1984, Nucleic Acids Research [nucleic acid research] 12: 387). The example of other software that can carry out sequence comparison includes, but is not limited to, BLAST package (see Ausubel et al., 1999 ibid-Chapter 18), FASTA (Atschul et al., 1990, J.Mol.Biol. [Molecular Biology Journal], 403-410) and GENEWORKS comparison tool suite. Both BLAST and FASTA can be used for offline and online search (see Ausubel et al., 1999 ibid, 7-58 pages to 7-60 pages). Percentage (%) of sequence homology can be calculated on continuous sequences, i.e., one sequence is aligned with other sequences, and each amino acid or nucleotide in one sequence is directly compared with the corresponding amino acid or nucleotide in the other sequences, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only on a relatively short number of residues. Although this is a very simple and reliable method, it does not take into account that, for example, in a pair of sequences that are originally identical, an insertion or deletion can cause the subsequent amino acid residues to no longer align, which may cause % homology to be greatly reduced when a global alignment is performed. Therefore, most sequence comparison methods are designed to produce an optimal alignment that takes into account possible insertions and deletions, thereby not unduly impairing the overall homology or identity score. This is achieved by inserting "gaps" in the sequence alignment in an attempt to maximize local homology or identity. However, these more complex methods assign a "gap penalty" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting a higher relatedness between the two compared sequences - can achieve a higher score than a sequence alignment with many gaps. Typically, an "affine gap cost" is used, which charges a relatively high cost for the presence of a gap, but charges a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. Of course, high gap penalties can produce optimal alignments with fewer gaps. Most alignment programs allow gap penalties to be modified. However, it is preferred to use the default values ​​when using such software for sequence comparisons. For example, when using the GCG Wisconsin Bestfit package, the default gap penalties for amino acid sequences are: -12 for a gap, -4 for each gap extension. Therefore, the calculation of maximum % homology first requires producing an optimal alignment taking into account the gap penalties.A new tool called BLAST 2 Sequences can also be used to compare protein and nucleotide sequences (see FEMS Microbiol Lett. 1999 174(2):247-50; FEMS Microbiol Lett. 1999 177(1):187-8 and the National Center for Biotechnology website at the National Institutes for Health website). Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pairwise comparison. Instead, a scaled similarity score matrix is ​​usually used, which assigns a score to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix that is commonly used is the BLOSUM62 matrix - the default matrix for the BLAST package. GCG The Wisconsin program typically uses public default values ​​or a custom symbol comparison table (if provided) (see the user manual for further details). For some applications, it is preferred to use the public default values ​​of the GCG software package, or in the case of other software, use a default matrix such as BLOSUM62. Alternatively, an algorithm similar to CLUSTAL is used in DNASIS. TMThe percentage of homology is calculated using the multiple alignment feature in Hitachi software (Higgins DG and Sharp PM (1988), Gene 73 (1), 237-244). Once the software has produced the best alignment, % homology, preferably % sequence identity, can be calculated. Typically, the software performs this calculation as part of the sequence comparison and generates a numerical result. The sequence may also have deletions, insertions or substitutions of amino acid residues that produce silent changes and produce functionally equivalent substances. Intentional amino acid substitutions can be made based on the similarity of amino acid properties (such as the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic properties of the residues), and it is therefore useful to group amino acids together in functional groups. Amino acids can be grouped together based solely on their side chain properties. However, it would also be more useful to include mutation data. For structural reasons, the groups of amino acids derived may therefore be conservative. These groups can be described in the form of a Venn diagram (Livingstone CD and Barton GJ (1993) "Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation" Comput. Appl. Biosci. 9:745-756) (Taylor WR (1986) "The classification of amino acid conservation" J. Theor. Biol. 119; 205-218). Conservative substitutions can be made, for example, according to the following table, which describes generally accepted Venn diagram groupings of amino acids.

[0046] As used herein, the terms "polypeptide" and "peptide" are used interchangeably herein and refer to polymers of amino acids of any length. A polymer can be linear or branched, it can contain modified amino acids, and it can be interrupted by non-amino acids. A protein can have one or more polypeptides. The term also encompasses amino acid polymers that have been modified; for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.

[0047] As used herein, "variant" is interpreted to mean a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, respectively, but retains essential properties. A typical variant of a polynucleotide differs from another reference polynucleotide in nucleic acid sequence. Changes in the nucleic acid sequence of a variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. As discussed below, nucleotide changes can result in amino acid substitutions, additions, deletions, fusions, and truncations in a polypeptide encoded by a reference sequence. A typical variant of a polypeptide differs from another reference polypeptide in amino acid sequence. Typically, the differences are limited, so that the sequences of the reference polypeptide and the variant are generally very similar and, in many regions, are identical. A variant and a reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, or deletions in any combination. The substituted or inserted amino acid residues may or may not be amino acid residues encoded by the genetic code. A variant of a polynucleotide or polypeptide may be naturally occurring, such as an allelic variant, or it may be a variant known not to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides can be prepared by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to those skilled in the art.

[0048] As used herein, the terms "upstream" and "downstream" refer to the relative positions within a sequence of individual nucleotides in a nucleic acid (e.g., DNA). Typically, a first sequence "upstream" of a second sequence means that the first sequence is 5' of the second sequence, while a first sequence "downstream" of a second sequence means that the first sequence is 3' of the second sequence.

[0049] As used herein, the term "wild type" has the meaning commonly understood by those skilled in the art, i.e., refers to the typical form of an organism, strain, gene, or trait as it occurs in nature, distinguishing it from mutants or variants. It can be isolated from a source in nature without being intentionally modified.

[0050] As used herein, the terms "non-naturally occurring" and "engineered" are used interchangeably and refer to the presence of human effort. When these terms are used to describe a nucleic acid or polypeptide, it means that the nucleic acid or polypeptide is at least substantially free from at least one other component with which it is found in nature or with which it is associated in nature.

[0051] As used herein, "cell" is understood to refer not only to a particular individual cell, but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in subsequent generations due to mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term.

[0052] As used herein, the term "in vivo" refers to the body of an organism, while the term "ex vivo" or "in vitro" refers to outside of an organism.

[0053] As used herein, the term "treatment" refers to a method for obtaining beneficial or desired results (including clinical results). For the purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviating one or more symptoms caused by the disease, reducing the extent of the disease, stabilizing the disease (e.g., preventing or delaying the worsening of the disease), preventing or delaying the spread of the disease (e.g., metastasis), preventing or delaying the recurrence of the disease, reducing the recurrence rate of the disease, delaying or slowing down the progress of the disease, improving the disease state, providing relief (partial or complete) of the disease, reducing the dosage of one or more other drugs required for treating the disease, delaying disease progression, increasing quality of life and / or prolonging survival." treatment" also encompasses the pathological results that reduce disease (e.g., cancer). The method of this disclosure contemplates any one or more of these therapeutic aspects of treatment.

[0054] As used herein, the term "disease" includes the terms "disorder" and "condition" and is not limited to medically well-defined terms.

[0055] As used herein, reference to a value or parameter that is "not" generally means and describes a value or parameter that is "different from." For example, a method is not for treating cancer type X, which means that the method can be used to treat cancers other than type X.

[0056] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0057] As used herein, the term "and / or" in phrases such as "A and / or B" is intended to include both A and B; A or B; A (alone); and B (alone). Similarly, the term "and / or" in phrases such as "A, B and / or C" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0058] As used herein, when the term "about" precedes a series of numbers (e.g., about 1, 2, 3), it is understood that each of the numbers in the series is modified by the term "about" (i.e., about 1, about 2, about 3). The term "about XY" as used herein has the same meaning as "about X to about Y."

[0059] It should be understood that the embodiments of the present disclosure described herein include "consisting of" and / or "consisting essentially of" the embodiments.

[0060] It is also noted that the claims may be drafted to exclude any optional element. Thus, this statement is intended to serve as a precondition for using exclusive terminology such as "solely," "only," and the like in connection with the recitation of claim elements, or using a "negative" limitation. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] An understanding of certain features and advantages of the present disclosure will be gained by referring to the following detailed description, which sets forth illustrative embodiments in which the principles of the present disclosure may be utilized, and to the accompanying drawings, in which:

[0062] Figures 1A-1C Schematic illustration (not to scale) of constructs expressing hfCas13f v2 and sgRNA[MECP2] or sgRNA[NT] containing one or two spacers (as a negative control), with mCherry as a reporter.

[0063] Figures 2A-2C A graph shows in vitro knockdown of MECP2 mRNA levels by hfCas13f v2-sgRNA[MECP2] compared to a negative control. MECP2 mRNA levels were detected by RT-qPCR. N = 3-4 per group. *, P < 0.05; **, P < 0.01.

[0064] Figure 3A is a schematic (not to scale) illustration of an AAV.PHP.eB construct expressing hfCas13f v2 and sgRNA [MECP2] containing two spacers 9&3; Figure 3B Schematic diagram showing unilateral stereotactic injection of AAV particles into the mouse hippocampus; Figures 3C-3E The middle panel shows in vivo knockdown of MECP2 mRNA and protein levels by stereotactic injection of AAV.PHP.eB particles delivering hfCas13f v2-sgRNA[MECP2]9&3 into the hippocampal dermal growth factor (DG) region of C57BL / 6 mice compared to untreated mice. MECP2 mRNA and protein levels were measured by RT-qPCR and IF, respectively. N = 4 / group. **, P < 0.01; ***, P < 0.001.

[0065] Figure 4A is a schematic (not to scale) illustration of an AAV.PHP.eB construct expressing hfCas13f v2.5 and sgRNA [MECP2] containing two spacers 9&3; Figure 4B Schematic diagram showing unilateral stereotactic injection of AAV particles into the hippocampus of C57BL / 6 mice; Figures 4C-4EThe middle panel shows in vivo knockdown of MECP2 mRNA and protein levels by stereotactic injection of AAV.PHP.eB particles delivering hfCas13f v2.5-sgRNA[MECP2]9&3 into the Hip DG region of C57BL / 6 mice, compared to the uninjected side of the same Hip as a negative control. MECP2 mRNA and protein levels were measured by RT-qPCR and IF, respectively. N = 2-3 / group. **, P < 0.01.

[0066] Figures 5A-5C Figure 2 shows the infection efficiency of AAV.PHP.eB particles delivering the hfCas13f v2.5 system in MDS mice with ICV administration. Figure 5B ), Western blot ( Figure 5C ) and IF( Figure 5A ) Detection of hfCas13f v2.5 tagged with HA; Figure 5D Schematic (not to scale) illustration of the AAV.PHP.eB construct expressing hfCas13f v2.5 and sgRNA[MECP2] or sgRNA[NT] containing two spacers 9&3 (as a negative control).

[0067] Figures 6A-6C The middle panel shows in vivo knockdown of MECP2 by ICV administration of AAV.PHP.eB particles delivered by the hfCas13f v2.5 system into the lateral ventricle to infect the whole brain of MDS mice, compared to a negative control of ICV injection of control AAV.PHP.eB particles. MECP2 protein levels were detected by Western blotting and IF. N = 2-3 / group in Western blotting experiments.

[0068] Figures 7A-7B It is shown that abnormal locomotion and anxiety-like behaviors of MDS mice were partially rescued at week 4 or week 8 after ICV administration. N=5 / group.

[0069] Figures 8A-8D Abnormal motor and social behaviors of MDS mice were reversed at week 10 after ICV administration. N=5 / group. *, P<0.05; **, P<0.01; ****, P<0.0001.

[0070] Figure 9 It was shown that no toxicity of AAV.PHP.eB particles was observed 7 weeks after AAV ICV administration.

[0071] Figure 10is a schematic diagram showing an exemplary dsDNA, an exemplary RNA transcript transcribed from the dsDNA, an exemplary guide nucleic acid, and an exemplary napRNAn, wherein the guide sequence is reverse complementary to the target sequence.

[0072] Figure 11 is a schematic diagram showing an exemplary dsDNA, an exemplary RNA transcript transcribed from the dsDNA, an exemplary guide nucleic acid, and an exemplary napRNAn, wherein the guide sequence is reverse complementary to and contains mismatches to a target sequence.

[0073] Figure 12-14 Comparison of hfCas13f.1v2 and v3 is shown.

[0074] Figure 15 Shown are the whole transcriptome sequencing results of hfCas13f.1v3.

[0075] The drawings herein are for illustration purposes only and are not necessarily drawn to scale. DETAILED DESCRIPTION

[0076] Overview

[0077] The present disclosure provides tools and methods for treating MECP2-related diseases such as MECP2 Duplication Syndrome (MDS).

[0078] In particular, the present disclosure provides tools for downregulating the expression of the MECP2 gene by cleaving / degrading MECP2 mRNA. Such tools can be delivered to subjects in need, for example, via AAV vectors and intracerebroventricular injection. Exemplary constructs disclosed herein have demonstrated efficacy in knocking down MECP2 mRNA levels (particularly in vivo) and improving disease phenotypes in mouse models, thereby opening the door to gene therapy for treating MECP2-related diseases such as MDS.

[0079] Guide nucleic acid

[0080] In one aspect, the present disclosure provides a guide nucleic acid comprising:

[0081] (1) a scaffold sequence capable of forming a complex with a nucleic acid programmable RNA nuclease (napRNAn), and

[0082] (2) A guide sequence capable of hybridizing to a target sequence of human MECP2 mRNA to guide the complex to the human MECP2 mRNA.

[0083] System or combination

[0084] In another aspect, the present disclosure provides a system or composition comprising:

[0085] (1) a guide nucleic acid or a polynucleotide encoding the guide nucleic acid, the guide nucleic acid comprising:

[0086] (a) a scaffold sequence capable of forming a complex with a nucleic acid programmable RNA nuclease (napRNAn), and

[0087] (b) a guide sequence capable of hybridizing to a target sequence of human MECP2 mRNA to guide the complex to the human MECP2 mRNA; and

[0088] (2) The napRNAn or a polynucleotide encoding the napRNAn.

[0089] In some embodiments, the system is a complex comprising a napRNAn complexed with a guide nucleic acid.

[0090] In some embodiments, the complex further comprises human MECP2 mRNA hybridized to the target sequence.

[0091] rAAV vector genome

[0092] In yet another aspect, the present disclosure provides a recombinant adeno-associated virus (rAAV) vector genome, the rAAV vector genome comprising:

[0093] (a) a first polynucleotide sequence comprising a first sequence encoding a first guide nucleic acid comprising:

[0094] (1) a scaffold sequence capable of forming a complex with a nucleic acid programmable RNA nuclease (napRNAn), and

[0095] (2) a first guide sequence capable of hybridizing to a first target sequence of human MECP2 mRNA to guide the complex to the first guide sequence of the human MECP2 mRNA; and

[0096] (b) a second polynucleotide sequence comprising a sequence encoding the napRNAn,

[0097] The rAAV vector genome is suitable for encapsulation into recombinant AAV particles.

[0098] Multiple guide nucleic acids

[0099] The systems, compositions, or rAAV vector genomes of the present disclosure can comprise or encode one guide nucleic acid or encode more than one nucleic acid, e.g., for the purpose of increasing the efficiency of cleavage against human MECP2 mRNA.

[0100] In some embodiments, the first polynucleotide sequence further comprises a second sequence encoding a second guide nucleic acid comprising:

[0101] (1) a scaffold sequence capable of forming a complex with napRNAn or the scaffold sequence capable of forming a complex with napRNAn, and

[0102] (2) a second guide sequence capable of hybridizing to a second target sequence of human MECP2 mRNA to guide the complex to the human MECP2 mRNA.

[0103] In some embodiments, the first polynucleotide sequence further comprises a third sequence encoding a third guide nucleic acid comprising:

[0104] (1) a scaffold sequence capable of forming a complex with napRNAn or the scaffold sequence capable of forming a complex with napRNAn, and

[0105] (2) capable of hybridizing to a third target sequence of human MECP2 mRNA to guide the complex to a third guide sequence of human MECP2 mRNA.

[0106] In some embodiments, the first polynucleotide sequence further comprises a fourth sequence encoding a fourth guide nucleic acid comprising:

[0107] (1) a scaffold sequence capable of forming a complex with napRNAn or the scaffold sequence capable of forming a complex with napRNAn, and

[0108] (2) capable of hybridizing to a fourth target sequence of human MECP2 mRNA to guide the complex to the fourth guide sequence of human MECP2 mRNA.

[0109] In some embodiments, the first polynucleotide sequence further comprises a fifth guide nucleic acid, a sixth guide nucleic acid, a seventh guide nucleic acid, etc.

[0110] In some embodiments using the same napRNAn, the scaffold sequences of the more than one guide nucleic acids can be the same or slightly different (e.g., differing by no more than 5, 4, 3, 2, or 1 nucleotides) to be compatible with the same napRNAn. In some embodiments using different napRNAn, the scaffold sequences of the more than one guide nucleic acids can be different to be compatible with different napRNAn.

[0111] Properties of the Guide Nucleic Acids of the Disclosure

[0112] In some embodiments, the guide nucleic acid (e.g., a guide nucleic acid, a first guide nucleic acid, a second guide nucleic acid, a third guide nucleic acid, a fourth guide nucleic acid, etc.; as elsewhere) is RNA. In some embodiments, the guide nucleic acid comprises a modification. In some embodiments, the guide nucleic acid is an unmodified RNA or a modified RNA. In some embodiments, the guide nucleic acid is a modified RNA containing modified ribonucleotides. In some embodiments, the guide nucleic acid is a modified RNA containing deoxyribonucleotides. In some embodiments, the guide nucleic acid is a modified RNA containing modified deoxyribonucleotides. In some embodiments, the guide nucleic acid comprises modified or unmodified deoxyribonucleotides and modified or unmodified ribonucleotides.

[0113] Mechanism of the present disclosure

[0114] Methyl-CpG binding protein 2 (MeCP2) is an epigenetic regulator crucial for normal brain development and function. It is encoded by the dosage-sensitive MECP2 gene, which is implicated in two devastating childhood neurodevelopmental disorders. Loss-of-function mutations in the MECP2 gene cause Rett syndrome (RTT), while duplications on chromosome Xq28 that span the MECP2 gene cause MECP2 duplication syndrome (MDS).

[0115] MDS is one of the most common subtelomeric genomic rearrangements in males, accounting for approximately 1% of X-linked intellectual disability cases. MDS is inherited in an X-linked manner and is considered to be fully penetrant in males. The main features of MDS include infantile hypotonia, intellectual disability, anxiety, motor dysfunction, epilepsy (approximately 50% of affected individuals) and recurrent respiratory infections (approximately 75%). Approximately half of affected individuals die before the age of 25, usually from respiratory infections. However, this statistic underestimates the proportion of early deaths because most patients are young children. To date, more than 600 cases have been reported worldwide, and the clinicopathology is consistent in all reports.

[0116] MeCP2 regulates gene expression by binding to methylated DNA. Recent findings indicate that the transcription factor 20 (TCF20) complex interacts with MeCP2 at the chromatin interface and modifies MeCP2-induced synaptic and behavioral defects. Studies have shown that hundreds of genes can be regulated by MeCP2 in a cell-specific manner. Although MeCP2 is ubiquitously expressed in various human tissues, it is abundantly expressed in the brain, with neurons having the highest levels of MeCP2. Overexpression of MeCP2 may have deleterious effects on brain development, as shown in mouse models and patients with myelodysplastic syndrome (MDS).

[0117] A lifelong multidisciplinary approach is recommended for patients with MDS. Existing therapies are often symptomatic and have limited efficacy. For example, 82% of MDS-associated epilepsy is treatment-refractory and consistent with epileptic encephalopathy. Because clinical symptoms tend to worsen with age, the burden on MDS parents and their caregivers is significant, with primary concerns related to lack of effective communication, abnormal walking / balance problems, and seizures. Therefore, there remains a high unmet clinical need for treatments for MDS.

[0118] As described above, the guide sequence of the guide nucleic acid is designed to hybridize with human MECP2 mRNA, thereby directing the complex comprising the guide nucleic acid and napRNAn to the human MECP2 mRNA. In some embodiments, directing the complex to the human MECP2 mRNA enables napRNAn to specifically cleave the human MECP2 mRNA. In some embodiments, the specific cleavage of the human MECP2 mRNA results in degradation of the human MECP2 mRNA. With appropriate reductions in human MECP2 mRNA levels, it is reasonable to expect that a syndrome in a subject caused by inappropriate human MECP2 mRNA levels may be alleviated.

[0119] Design of target sequences and target sites disclosed herein

[0120] For purposes of this disclosure, in some embodiments, a target sequence (eg, a target sequence, a first target sequence, a second target sequence, a third target sequence, a fourth target sequence, etc.; as elsewhere) is positioned such that human MECP2 mRNA is specifically cleaved by napRNAn.

[0121] To facilitate evaluation of the designed target sequence in a mouse model, in some embodiments, the target sequence is positioned so that mouse MECP2 mRNA is specifically cleaved by napRNAn. In some embodiments, the target sequence is positioned so that both human MECP2 mRNA and mouse MECP2 mRNA are specifically cleaved by napRNAn. That is, the target sequence is selected to have cross-reactivity with both humans and mice.

[0122] As used herein, the term "MECP2 mRNA" includes MECP2 mRNA and any variants, derivatives, or ancestors thereof, including MECP2 pre-mRNA and any transcripts or isoforms produced from the MECP2 gene or MECP2 pre-mRNA by, for example, alternative promoter usage, alternative splicing, alternative initiation, and any naturally occurring variants or processed products thereof. In some embodiments, human MECP2 mRNA comprises the sequence of SEQ ID NO: 60.

[0123] Structure of the guide nucleic acids disclosed herein

[0124] In some embodiments, a guide nucleic acid comprises a scaffold sequence 5' or 3' to a guide sequence (e.g., a guide sequence, a first guide sequence, a second guide sequence, a third guide sequence, a fourth guide sequence, etc.; as elsewhere). In some embodiments, a guide nucleic acid comprises a scaffold sequence 3' to a guide sequence. In some embodiments, a scaffold sequence is fused to a guide sequence without a linker.

[0125] In some embodiments, a guide nucleic acid comprises, from 5' to 3', a guide sequence and a scaffold sequence.

[0126] In some embodiments, a guide nucleic acid comprises, from 5' to 3', a scaffold sequence, a guide sequence, and a scaffold sequence, wherein the scaffold sequences are the same or different.

[0127] In some embodiments, the guide nucleic acid comprises, from 5' to 3', one scaffold sequence, one guide sequence, one scaffold sequence, and one guide sequence, wherein the scaffold sequences are the same or different, and wherein the guide sequences are the same or different.

[0128] In some embodiments, a guide nucleic acid comprises, from 5' to 3', one scaffold sequence, one guide sequence, one scaffold sequence, one guide sequence, and one scaffold sequence, wherein the scaffold sequences are the same or different, and wherein the guide sequences are the same or different.

[0129] In some embodiments, a guide nucleic acid comprises, from 5' to 3', one scaffold sequence, one guide sequence, one scaffold sequence, one guide sequence, one scaffold sequence, and one guide sequence, wherein the scaffold sequences are the same or different, and wherein the guide sequences are the same or different.

[0130] The lengths of the target and guide sequences disclosed herein

[0131] In some embodiments, the target sequence is at least about 14 nucleotides in length, for example, about 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 or more nucleotides in length, or a range of values ​​between any two of the foregoing values ​​in length, for example, about 16 to about 50 nucleotides in length. In some embodiments, the target sequence is about 30 nucleotides in length.

[0132] In some embodiments, the target sequence comprises, consists essentially of, or consists of at least about 14 consecutive nucleotides of human MECP2 mRNA (e.g., about 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, or more consecutive nucleotides of human MECP2 mRNA, or a range of values ​​between any two of the foregoing values, e.g., about 14 to about 50 consecutive nucleotides of human MECP2 mRNA). In some embodiments, the target sequence comprises, consists essentially of, or consists of about 30 contiguous nucleotides of human MECP2 mRNA.

[0133] 65, 66, 67, 68, 69, 70 or more nucleotides in length, or a range of values ​​between any two of the foregoing values, for example, about 16 to about 50 nucleotides in length. In some embodiments, the guide sequence is about 30 nucleotides in length.

[0134] In some embodiments, the guide sequence is at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% (perfectly) complementary to the target sequence, optionally about 100% (perfectly) complementary; or wherein the guide sequence is at least about 100% complementary to the target sequence; or wherein the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 69 or 70 nucleotides do not contain a mismatch with the target sequence. It is generally believed that for the napRNAn (e.g., Cas13) of the present disclosure, at least two mismatches between the guide sequence and the target sequence can be tolerated without significantly reducing the cleavage activity. In some embodiments, the guide sequence is 100% (completely) complementary to the target sequence.

[0135] Specific embodiments of the target sequence and guide sequence disclosed herein

[0136] In some embodiments, the target sequence comprises, consists essentially of, or consists of: (1) the sequence of any one of SEQ ID NOs: 1-10, or a 5' or 3' truncation thereof truncated by 1, 2, 3, 4, 5, or 6 nucleotides at the 5' or 3' end; or (2) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% sequence identity to any one of SEQ ID NOs: 1-10, or a 5' or 3' truncation thereof truncated by 1, 2, 3, 4, 5, or 6 nucleotides at the 5' or 3' end; or (3) a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide differences, whether contiguous or not, compared to any one of SEQ ID NOs: 1-10.

[0137] In some embodiments, the target sequence comprises the sequence of SEQ ID NO: 29 or 35.

[0138] In some embodiments, the guide sequence comprises, consists essentially of, or consists of: (1) the sequence of any one of SEQ ID NOs: 17-26, or a 5' or 3' truncation thereof by 1, 2, 3, 4, 5, or 6 nucleotides at the 5' or 3' end; or (2) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% sequence identity to any one of SEQ ID NOs: 17-26, or a 5' or 3' truncation thereof by 1, 2, 3, 4, 5, or 6 nucleotides at the 5' or 3' end; or (3) a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide differences, whether contiguous or not, compared to any one of SEQ ID NOs: 17-26.

[0139] In some embodiments, the guide sequence comprises the sequence of SEQ ID NO: 19 or 25.

[0140] Specific embodiments of the scaffold sequence disclosed herein

[0141] For purposes of the present disclosure, support sequence is compatible with napRNAn of the present disclosure, and can be compounded with napRNAn. Support sequence can be the naturally occurring support sequence identified together with napRNAn or its variant that maintains the ability compounded with napRNAn. Usually, as long as the secondary structure of variant is substantially the same as the secondary structure of naturally occurring support sequence, just can maintain the ability compounded with napRNAn. Nucleotide deletion, insertion or replacement in the primary sequence of support sequence may not necessarily change the secondary structure of support sequence (for example, the relative position and / or size of the stem, projection and ring of support sequence can not significantly deviate from the relative position and / or size of original stem, projection and ring). For example, nucleotide deletion, insertion or replacement can be in the projection or loop region of support sequence, so that projection and therefore the overall symmetry of secondary structure roughly keep identical. Nucleotide deletion, insertion or replacement can also be in the stem of support sequence, so that the length of stem does not significantly deviate from the length of original stem (for example, in each of two stems, add or lack a base pair corresponding to 4 base changes in total).

[0142] In some embodiments, the scaffold sequence has a secondary structure that is substantially identical to the secondary structure of the sequence of SEQ ID NO:6.

[0143] In some embodiments, the scaffold sequence comprises, consists essentially of, or consists of a sequence that has at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO: 6, or a sequence that has at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide differences, whether contiguous or not, compared to the sequence of SEQ ID NO: 6.

[0144] In some embodiments, the scaffold sequence comprises the sequence of SEQ ID NO:6.

[0145] Specific embodiments of the guide nucleic acid disclosed herein

[0146] In some embodiments, a guide nucleic acid comprises, consists essentially of, or consists of a sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of any one of SEQ ID NOs: 7-16 and 37-40; or a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide differences, whether contiguous or not, compared to the sequence of any one of SEQ ID NOs: 7-16 and 37-40.

[0147] In some embodiments, the guide nucleic acid comprises the sequence of SEQ ID NO:37.

[0148] Regulation of the first polynucleotide sequence of the rAAV vector genome of the present disclosure

[0149] In some embodiments, the first polynucleotide sequence comprises a promoter operably linked to a sequence encoding a guide nucleic acid.

[0150] In some embodiments, the promoter is a ubiquitous promoter, a tissue-specific promoter, a cell-type-specific promoter, a constitutive promoter, or an inducible promoter.

[0151] Suitable promoters are known in the art and include, for example, Cbh promoter, Cba promoter, pol I promoter, pol II promoter, pol III promoter, T7 promoter, U6 promoter, H1 promoter, retroviral Rous sarcoma virus LTR promoter, cytomegalovirus (CMV) promoter, SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, elongation factor 1 alpha short (EFS) promoter, beta glucuronidase (GUSB) promoter, cytomegalovirus (CMV) immediate early (le) enhancer and / or promoter, chicken β-actin (CBA) promoter or derivatives thereof such as CAG promoter, CB promoter, (human) elongation factor 1 alpha-subunit (EF1 alpha) promoter, ubiquitin C (UBC) promoter, prion promoter, neuron-specific enolase (NSE), neurofilament light chain (NFL) promoter, neurofilament heavy chain (NFH) promoter, Platelet-derived growth factor (PDGF) promoter, platelet-derived growth factor B chain (PDGF-β) promoter, synaptophysin (Syn) promoter, synaptophysin 1 (Syn1) promoter, methyl-CpG binding protein 2 (MeCP2) promoter, Ca2+ / calmodulin-dependent protein kinase II (CaMKII) promoter, metabotropic glutamate receptor 2 (mGluR2) promoter, neurofilament light chain (NFL) promoter, neurofilament heavy chain (NFH) promoter, β-globin minigene nβ2 promoter, preproenkephalin (PPE) promoter, enkephalin (Enk) promoter, excitatory amino acid transporter 2 (EAAT2) promoter, glial fibrillary acidic protein (GFAP) promoter and myelin basic protein (MBP) promoter. In some embodiments, the promoter is a U6 promoter.

[0152] In some embodiments, the promoter comprises, consists essentially of, or consists of a sequence that has at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO: 49; or a sequence that has at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide differences, whether contiguous or not, from the sequence of SEQ ID NO: 49.

[0153] In some embodiments, the first polynucleotide sequence comprises, from 5′ to 3′, the promoter of SEQ ID NO: 49 and a sequence encoding the guide nucleic acid of any one of SEQ ID NOs: 7-16 and 37-40.

[0154] napRNAn of the present disclosure

[0155] For the purposes of the present disclosure, napRNAn can form a complex with the guide nucleic acid of the present disclosure by complexing with the scaffold sequence of the guide nucleic acid, and thereby be guided to human MECP2 mRNA through hybridization of the guide sequence of the guide nucleic acid with the target sequence of human MECP2 mRNA. When napRNAn is guided to human MECP2 mRNA, the nuclease activity of napRNAn acts to cleave human MECP2 mRNA, thereby promoting the degradation of human MECP2 mRNA. Generally, any such napRNAn can be used with the guide nucleic acid of the present disclosure, and when selecting napRNAn, a scaffold sequence that is compatible with napRNAn for complexing with napRNAn can also be selected accordingly. Scaffold sequences are generally conserved.

[0156] In some embodiments, the napRNAn is a class 2 type VI CRISPR-associated protein (Cas13). Cas13, a class 2 type VI RNA endonuclease, can bind to and cleave single-stranded RNA guided by an engineered CRISPR RNA (crRNA). Gene therapies based on RNA-targeted nucleases are currently being explored as safer alternatives to Cas endonucleases that edit DNA because they carry a lower risk of introducing permanent genomic changes.

[0157] In some embodiments, Cas13 is Cas13a (C2c2), Cas13b (such as Cas13b1, Cas13b2), Cas13c, Cas13d, Cas13e or Cas13f polypeptide. To date, Cas13f.1 (Cas13Y.1, Cas13Y) is one of the smallest known crRNA-guided RNA endonucleases, with only 790 amino acids, and several high-fidelity variants of this Cas (collectively referred to as hfCas13f.1 (hfCas13Y.1)) have been shown to exhibit high on-target activity and significantly lower side-cutting activity.

[0158] In some embodiments, the napRNAn comprises, consists essentially of, or consists of a sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO: 1, 2, 4, or 61, or an N-terminal truncation thereof without the first N-terminal methionine, and retains at least 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) of the guide sequence-specific RNA cleavage activity of the sequence of SEQ ID NO: 1, 2, 4, or 61.

[0159] In some embodiments, the napRNAn comprises the sequence of SEQ ID NO:61.

[0160] In some embodiments, the sequence encoding the napRNAn comprises, consists essentially of, or consists of a sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO: 3, 5, or 62, or a 5'-end truncation thereof without the first 5'ATG codon, and wherein the napRNAn encoded by the sequence retains at least 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) of the guide sequence-specific RNA cleavage activity of the sequence of SEQ ID NO: 3, 5, or 62.

[0161] In some embodiments, the sequence encoding napRNAn comprises the sequence of SEQ ID NO:62.

[0162] Regulation of the second polynucleotide sequence of the present disclosure

[0163] In some embodiments, the second polynucleotide sequence comprises a promoter operably linked to the sequence encoding napRNAn.

[0164] In some embodiments, the promoter is a broad spectrum promoter, a tissue-specific promoter, a cell type-specific promoter, a constitutive promoter, or an inducible promoter.

[0165] Suitable promoters are known in the art and include, for example, the Cbh promoter, the Cba promoter, the pol I promoter, the pol II promoter, the pol III promoter, T7 promoter, U6 promoter, H1 promoter, retroviral Rous sarcoma virus LTR promoter, cytomegalovirus (CMV) promoter, SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, elongation factor 1α short (EFS) promoter, β-glucuronidase (GUSB) promoter, cytomegalovirus (CMV) immediate early (Ie) enhancer and / or promoter, chicken β-actin (CBA) promoter or its derivatives such as CAG promoter, CB promoter, (human) elongation factor 1α-subunit (EF1α) promoter, ubiquitin C (UBC) promoter, prion promoter, neuron-specific enolase (NSE), neurofilament light chain (NFL) promoter, neurofilament heavy chain (NFH) promoter, platelet-derived growth factor (PDGF) promoter, platelet-derived growth factor B chain (PDG F-β) promoter, synapsin (Syn) promoter, synapsin 1 (Syn1) promoter, methyl-CpG binding protein 2 (MeCP2) promoter, Ca2+ / calmodulin-dependent protein kinase II (CaMKII) promoter, metabotropic glutamate receptor 2 (mGluR2) promoter, neurofilament light chain (NFL) promoter, neurofilament heavy chain (NFH) promoter, β-globin minigene nβ2 promoter, preproenkephalin (PPE) promoter, enkephalin (Enk) promoter, excitatory amino acid transporter 2 (EAAT2) promoter, glial fibrillary acidic protein (GFAP) promoter, myelin basic protein (MBP) promoter, HTT promoter, GRK1 promoter, CRX promoter, NRL promoter, MECP2 promoter, mMECP2 promoter, hMECP2 promoter, and RCVRN promoter.

[0166] In some embodiments, the promoter is a neural cell (eg, neuron)-specific promoter, such as the MECP2 promoter.

[0167] In some embodiments, the promoter is a Cbh promoter, a CMV promoter, an mMECP2 promoter, or an hMECP2 promoter.

[0168] In some embodiments, the second polynucleotide sequence comprises a Kozak sequence 5' to the sequence encoding napRNAn.

[0169] In some embodiments, the second polynucleotide sequence comprises a sequence encoding a nuclear localization signal (NLS) 5' and / or 3' to the sequence encoding napRNAn.

[0170] In some embodiments, the second polynucleotide sequence comprises a sequence encoding a nuclear export signal (NES) 5' and / or 3' to the sequence encoding napRNAn.

[0171] In some embodiments, the second polynucleotide sequence comprises a sequence encoding a first NLS 5' to the sequence encoding napRNAn and a second sequence encoding a second NLS 3' to the sequence encoding napRNAn.

[0172] In some embodiments, the NLS, the first NLS, and / or the second NLS is an SV40 NLS, a bpSV40 NLS, or a nucleoplasmin NLS (npNLS).

[0173] In some embodiments, the second polynucleotide sequence comprises a WPRE sequence downstream of the sequence encoding napRNAn.

[0174] In some embodiments, the WPRE sequence is selected from the group consisting of a woodchuck hepatitis virus (WHP) post-transcriptional regulatory element (WPRE), WPRE3 (shortened WPRE), and functional variants thereof (eg, functional truncations).

[0175] In some embodiments, the second polynucleotide sequence comprises a sequence encoding a polyadenylation (polyA) signal downstream of the sequence encoding napRNAn.

[0176] In some embodiments, the second polynucleotide sequence comprises a WPRE sequence downstream of a sequence encoding napRNAn, followed by a sequence encoding a polyadenylation (polyA) signal.

[0177] In some embodiments, the polyA signal is selected from the group consisting of a bovine growth hormone polyadenylation (bGH polyA) signal, a small polyA (SPA) signal, a human growth hormone polyadenylation (hGH polyA) signal, an SV40 polyA (SV40polyA) signal, a rabbit beta globin polyA (rBG polyA) signal, and functional variants thereof (e.g., functional truncations).

[0178] In some embodiments, the polyA signal is a bGH polyA signal.

[0179] In some embodiments, the second polynucleotide sequence comprises, from 5' to 3', a promoter, a Kozak sequence, a first sequence encoding a first NLS, a sequence encoding napRNAn, a second sequence encoding a second NLS, a WPRE sequence, and a sequence encoding a polyA signal.

[0180] In some embodiments, the promoter comprises, consists essentially of, or consists of a sequence encoding a polypeptide having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO: 47, 58, or 64; or a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide differences, whether contiguous or not, from the sequence of SEQ ID NO: 47, 58, or 64.

[0181] In some embodiments, the Kozak sequence comprises, consists essentially of, or consists of a sequence that encodes a polypeptide having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO:54; or a sequence that has at most 1, 2, 3, or 4 nucleotide differences, whether contiguous or not, compared to the sequence of SEQ ID NO:54.

[0182] In some embodiments, the NLS, the first NLS and / or the second NLS comprises, consists essentially of, or consists of a sequence encoding a polypeptide having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to the sequence of SEQ ID NO: 47 or 58; or a sequence that has at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid differences, whether contiguous or not, compared to the sequence of SEQ ID NO: 47 or 58.

[0183] In some embodiments, the sequence encoding the NLS, the first sequence encoding the first NLS, and / or the second sequence encoding the second NLS comprises, consists essentially of, or consists of a sequence encoding a polypeptide having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to the sequence of SEQ ID NO: 64 or 65; or a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid differences, whether contiguous or not, compared to the sequence of SEQ ID NO: 64 or 65.

[0184] In some embodiments, the sequence encoding the polyA signal comprises, consists essentially of, or consists of a sequence encoding a polypeptide having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO: 48; or a sequence that differs from the sequence of SEQ ID NO: 48 in at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides, whether contiguous or not.

[0185] In some embodiments, the second polynucleotide sequence comprises, from 5' to 3', the promoter of SEQ ID NO:63, the Kozak sequence of SEQ ID NO:54, the first sequence encoding the first NLS of SEQ ID NO:64, a 5'-end truncation of the sequence encoding the napRNAn without the first 5'ATG codon of SEQ ID NO:62, the second sequence encoding the second NLS of SEQ ID NO:65, the WPRE sequence of SEQ ID NO:59, and the sequence encoding the polyA signal of SEQ ID NO:48.

[0186] ITRs of the rAAV vector genome of the present disclosure

[0187] In some embodiments, the rAAV vector genome comprises a 5' inverted terminal repeat (ITR) sequence and a 3' ITR sequence.

[0188] In some embodiments, the 5' ITR sequence and the 3' ITR sequence are both wild-type ITR sequences from the following: AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV-DJ, AAV PHP.eB, or a member of the evolutionary branch to which any one of AAV1-AAV13 belongs, or a functional variant (e.g., a functional truncation) thereof.

[0189] In some embodiments, the 5' ITR sequence comprises, consists essentially of, or consists of a sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO:52.

[0190] In some embodiments, the 3' ITR sequence comprises, consists essentially of, or consists of a sequence that has at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO:53.

[0191] Construction of the rAAV vector genome of the present disclosure

[0192] In some embodiments, the rAAV vector genome comprises, from 5' to 3', a first polynucleotide sequence and a second polynucleotide sequence.

[0193] In some embodiments, the rAAV vector genome comprises, from 5' to 3', the second polynucleotide sequence and the first polynucleotide sequence.

[0194] In some embodiments, the rAAV vector genome comprises, consists essentially of, or consists of a sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100%) sequence identity to the sequence of SEQ ID NO:56, 57, or 66.

[0195] In some embodiments, the rAAV vector genome comprises the sequence of SEQ ID NO:66.

[0196] rAAV particles of the present disclosure

[0197] In another aspect, the present disclosure provides a recombinant AAV (rAAV) particle comprising the rAAV vector genome of the present disclosure. A brief introduction to AAV for delivery can be found in the "Adeno-associated virus (AAV) Guide" (www.addgene.org / guides / aav / ).

[0198] Adeno-associated virus (AAV), when engineered for delivery of, for example, a protein coding sequence of interest, may be referred to as a (r)AAV vector, (r)AAV vector particle, or (r)AAV particle, where "r" stands for "recombinant." Furthermore, the genome packaged in an AAV vector for delivery may be referred to as a (r)AAV vector genome, vector genome, or simply vg, while viral genome may refer to the original viral genome of native AAV.

[0199] The serotype of the rAAV particle capsid can be matched to the type of target cell. For example, Table 2 of WO 2018002719A1 lists exemplary cell types that can be transduced by the indicated AAV serotypes (incorporated herein by reference).

[0200] In some embodiments, the rAAV particles include a capsid having a serotype suitable for delivery to neural cells (e.g., neurons). In some embodiments, the rAAV particles include a capsid of a serotype of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV-DJ, or AAV.PHP.eB, a member of a clade to which any one of AAV1-AAV13 belongs, or a functional variant thereof (e.g., a functional truncation), which encapsulates the rAAV vector genome. In some embodiments, the serotype of the capsid is AAV9 or AAV.PHP.eB or a mutant thereof.

[0201] The general principles of rAAV particle production are known in the art. In some embodiments, rAAV particles can be produced using the triple transfection method (described in detail in US Pat. No. 6,001,650).

[0202] Vector titer is typically expressed as vector genomes / ml (vg / ml). In some embodiments, the vector titer is greater than 1×10 9 , higher than 5×10 10 , higher than 1×10 11 , higher than 5×10 11 , higher than 1×10 12 , higher than 5×10 12 or higher than 1×10 13 vg / ml.

[0203] As an alternative to packaging single-stranded (ss) DNA sequences as vector genomes for rAAV particles, systems and methods for packaging RNA sequences as vector genomes into rAAV particles have recently been developed and can be applied herein. See PCT / CN2022 / 075366, which is incorporated herein by reference in its entirety.

[0204] When the vector genome is RNA, such as in PCT / CN2022 / 075366, for simplicity of description and declaration, the sequence elements described herein for the DNA vector genome, when present in the RNA vector genome, should generally be considered to be applicable to the RNA vector genome, except that the deoxyribonucleotides in the DNA sequence are the corresponding ribonucleotides in the RNA sequence (e.g., dT is equivalent to U, and dA is equivalent to A) and / or the elements in the DNA sequence are replaced with corresponding elements having corresponding functions in the RNA sequence, or are omitted because their functions are not required in the RNA sequence, and / or additional elements necessary for the RNA vector genome are introduced.

[0205] As used herein, a coding sequence (e.g., as a sequence element of an rAAV vector genome herein) is interpreted, understood, and considered to cover and encompass both DNA coding sequences and RNA coding sequences. When it is a DNA coding sequence, an RNA sequence can be transcribed from the DNA coding sequence, and optionally a protein can be further translated from the transcribed RNA sequence as needed. When it is an RNA coding sequence, the RNA coding sequence itself can be a functional RNA sequence for use, or an RNA sequence can be generated from the RNA coding sequence (e.g., by RNA processing), or a protein can be translated from the RNA coding sequence.

[0206] For example, a Cas13 coding sequence encoding a Cas13 polypeptide encompasses a Cas13 DNA coding sequence from which the Cas13 polypeptide is expressed (indirectly via transcription and translation) or a Cas13 RNA coding sequence from which the Cas13 polypeptide is translated (directly).

[0207] For example, a gRNA coding sequence encoding a gRNA encompasses a gRNA DNA coding sequence from which the gRNA is transcribed or a gRNA RNA coding sequence that (1) is itself a functional gRNA for use or (2) from which a gRNA is produced (e.g., by RNA processing).

[0208] In some embodiments of the rAAV RNA vector genome, the 5'-ITR and / or 3'-ITR may not be necessary as DNA packaging signals and may be at least partially omitted, but RNA packaging signals may be introduced.

[0209] In some embodiments of the rAAV RNA vector genome, the promoter driving transcription of the DNA sequence may not be necessary and may be at least partially omitted.

[0210] In some embodiments of the rAAV RNA vector genome, the sequence encoding the polyA signal may be unnecessary and may be at least partially omitted, but a polyA tail may be introduced.

[0211] Similarly, other DNA elements of the rAAV DNA vector genome can be omitted or replaced with corresponding RNA elements and / or additional RNA elements can be introduced to accommodate strategies for delivering RNA vector genomes by rAAV particles.

[0212] Pharmaceutical compositions of the present disclosure

[0213] In yet another aspect, the present disclosure provides a pharmaceutical composition comprising a system or composition of the present disclosure or an rAAV particle of the present disclosure, and a pharmaceutically acceptable excipient.

[0214] In some embodiments, the pharmaceutical composition comprises rAAV particles at a concentration selected from about 1×10 10 vg / mL, 2×10 10 vg / mL, 3×10 10 vg / mL, 4×10 10 vg / mL, 5×10 10 vg / mL, 6×10 10 vg / mL, 7×10 10 vg / mL、8×10 10 vg / mL, 9×10 10 vg / mL, 1×10 11 vg / mL, 2×10 11 vg / mL, 3×10 11 vg / mL, 4×10 11 vg / mL, 5×10 11 vg / mL, 6×10 11 vg / mL, 7×10 11 vg / mL、8×10 11 vg / mL, 9×10 11 vg / mL, 1×10 12 vg / mL, 2×10 12 vg / mL, 3×10 12 vg / mL, 4×10 12 vg / mL, 5×10 12 vg / mL, 6×10 12 vg / mL, 7×10 12 vg / mL、8×10 12 vg / mL, 9×10 12 vg / mL, 1×10 13 vg / mL, or a concentration in a numerical range between any two of the aforementioned values, such as about 9×10 10 vg / mL to about 8×10 11The concentration of vg / mL.

[0215] In some embodiments, the pharmaceutical composition is an injectable solution.

[0216] In some embodiments, the volume of the injection is selected from about 1 microliter, 10 microliters, 50 microliters, 100 microliters, 150 microliters, 200 microliters, 250 microliters, 300 microliters, 350 microliters, 400 microliters, 450 microliters, 500 microliters, 550 microliters, 600 microliters, 650 microliters, 700 microliters, 750 microliters, 800 microliters, 850 microliters, 900 microliters, 950 microliters, 1000 microliters, and volumes in a range of values ​​between any two of the foregoing values, for example, a concentration of about 10 microliters to about 750 microliters.

[0217] How to use the present disclosure

[0218] In yet another aspect, the present disclosure provides a method for preventing or treating a disease or disorder associated with human MECP2 mRNA in a subject in need thereof, the method comprising administering to the subject a system or composition of the present disclosure, an rAAV particle of the present disclosure, or a pharmaceutical composition of the present disclosure, wherein the napRNAn modifies the human MECP2 mRNA, and wherein the modification of the human MECP2 mRNA treats the disease or disorder.

[0219] In some embodiments, the disease or disorder is MECP2 Duplication Syndrome (MDS).

[0220] In some embodiments, administering comprises local administration or systemic administration.

[0221] In some embodiments, administration comprises intrathecal administration, intramuscular administration, intravenous administration, transdermal administration, intranasal administration, oral administration, mucosal administration, intraperitoneal administration, intracranial administration, intracerebroventricular administration, or stereotactic administration.

[0222] In some embodiments, the administering comprises intraventricular administration (eg, intraventricular injection).

[0223] In some embodiments, the administering is performed by injection.

[0224] In some embodiments, the subject is a human.

[0225] In some embodiments, the level of human MECP2 mRNA in the subject is reduced by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or more compared to the level of human MECP2 mRNA in the subject before the administration.

[0226] In some embodiments, the level of human MECP2 protein in the subject is at most about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, or about 85% compared to the level of human MECP2 protein in a human or population not suffering from the disease or disorder.

[0227] The dosage of rAAV particles used to treat the disease or disorder can be a single dose or multiple doses. It will be understood by those skilled in the art that the actual dosage can vary widely depending on a variety of factors, such as the vector choice, the target cell, organism, tissue, the general condition of the subject to be treated, the degree of transformation / modification sought, the route of administration, the mode of administration, the type of transformation / modification sought, etc.

[0228] In some embodiments, the rAAV particles are administered at a therapeutically effective dose. For example, a therapeutically effective dose of rAAV particles can be about 1.0E+8, 2.0E+8, 3.0E+8, 4.0E+8, 6.0E+8, 8.0E+8, 1.0E+9, 2.0E+9, 3.0E+9, 4.0E+9, 6.0E+9, 8.0E+9, 1.0E+10, 2.0E+10, 3.0E+10, 4.0E+10, 6.0E+10, 8.0E+10, 1.0E+11, 2.0E+11, 3.0E+11, 4.0E+11, 6.0E+11, 8.0E+11, 1.0E+12, 2.0E+12, 3.0E+12, 4.0E+12, 6.0E+13, 8.0E+14, 8.0E+15, 8.0E+16, 8.0E+17, 8.0E+18, 8.0E+19, 9. + 15, 1.0E+16, 2.0E+16, 3.0E+16, 4.0E+16, 6.0E+16, 8.0E+16, or 1.0E+17 vg, or a range within any two of these values. Vg represents the number of vector genomes per rAAV particle to be administered.

[0229] cell

[0230] In yet another aspect, the disclosure provides a cell or its progeny, the cell or its progeny comprising a guiding nucleic acid of the disclosure, a system or composition or complex of the disclosure, an rAAV vector genome of the disclosure, or an rAAV particle of the disclosure. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a human cell. In some embodiments, the cell is located in the CNS of a subject. In some embodiments, the cell is a human neural cell (e.g., a neuron).

[0231] In yet another aspect, the disclosure provides a cell or its progeny, which is modified by a system or composition or complex of the disclosure, an rAAV particle of the disclosure, or a method of the disclosure. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a human cell. In some embodiments, the cell is located in the CNS of a subject. In some embodiments, the cell is a human neural cell (e.g., a neuron).

[0232] In some embodiments, the cell is not a human embryonic stem cell.In some embodiments, the cell is not a human germ cell.

[0233] Reagent test kit

[0234] In yet another aspect, the present disclosure provides a kit comprising a guide nucleic acid of the present disclosure, a system or composition of the present disclosure, an rAAV vector genome of the present disclosure, an rAAV particle of the present disclosure, or a cell of the present disclosure or progeny thereof.

[0235] In some embodiments, the kit further includes instructions for using one or more components contained therein, and / or for combining with additional one or more components that may be obtained or required elsewhere.

[0236] In some embodiments, the kit further comprises one or more buffers that can be used to dissolve any one of the components contained therein and / or provide suitable reaction conditions for one or more of the components. Such buffers can include one or more of PBS, HEPES, Tris, MOPS, Na2CO3, NaHCO3, NaB, or a combination thereof. In some embodiments, the reaction conditions include a suitable pH, such as an alkaline pH. In some embodiments, the pH is between 7 and 10.

[0237] In some embodiments, any one or more of the kit components can be stored in a suitable container or at a suitable temperature, such as 4 degrees Celsius.

[0238] Further embodiments are described in the following examples, which are provided for illustrative purposes only and are not intended to limit the scope of the present disclosure.

[0239] The present disclosure provides the following additional embodiments.

[0240] One aspect of the present invention provides a recombinant adeno-associated virus (rAAV) vector genome, the rAAV vector genome comprising:

[0241] (1) a Cas13 coding sequence encoding a Cas13 polypeptide,

[0242] (i) wherein the Cas13 coding sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 3, 5 or 62 or its RNA counterpart,

[0243] (ii) wherein the Cas13 polypeptide comprises

[0244] (a) the amino acid sequence of SEQ ID NO: 2, 4 or 61, or

[0245] (b) a variant thereof having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 1 and having a non-conservative substitution at Y666 and / or Y677 of SEQ ID NO: 1 (e.g., a Y666A and / or Y677A substitution), wherein the variant has substantially the same (e.g., at least about 80%, 90%, 95%, 99% or more) guide RNA-specific nuclease activity (cleavage activity) as SEQ ID NO: 1 and substantially no (e.g., at most 20%, 15%, 10%, 5%) flanking (guide RNA-independent) nuclease activity (flanking activity) of SEQ ID NO: 1; and

[0246] (2) a single guide RNA (sgRNA) or an sgRNA coding sequence encoding the sgRNA, the sgRNA comprising:

[0247] (A) a spacer sequence that is substantially complementary to a target RNA sequence of MECP2 mRNA; and

[0248] (B) a direct repeat (DR) sequence capable of forming a complex with the Cas13 polypeptide;

[0249] wherein when the sgRNA guides the Cas13 polypeptide to the target RNA sequence, the complex specifically cleaves MECP2 mRNA at or near the target RNA sequence;

[0250] Optionally, the sgRNA or sgRNA encoding sequence is 3' or 5' to the Cas13 encoding sequence.

[0251] In some embodiments, the rAAV vector genome further comprises a first nuclear localization sequence (NLS, such as SEQ ID NO: 47 or 58) or a first coding sequence of a nuclear export signal (NES) fused to the N-terminus of the Cas13 polypeptide, and / or a second NLS (such as SEQ ID NO: 47 or 58) or a second coding sequence of NES fused to the C-terminus of the Cas13 polypeptide;

[0252] Optionally, the rAAV vector genome further comprises a coding sequence for an epitope tag such as one or more copies (e.g., 3 tandem copies) of an HA tag fused (e.g., via the C-terminus) to the Cas13 polypeptide (and C-terminal NLS or NES, if present).

[0253] In some embodiments, the rAAV vector genome further comprises a 5' AAV ITR sequence and a 3' AAV ITR sequence.

[0254] In some embodiments, both the 5' AAV ITR sequence and the 3' AAV ITR sequence are wild-type AAV ITR sequences from AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV-DJ, AAV PHP.eB, or a member of the clade to which any of said AAV1-AAV13 belongs, or a functional truncated variant thereof; optionally, the 5' AAV ITR sequence has the polynucleotide sequence of SEQ ID NO: 52, and / or the 3' AAV ITR sequence has the polynucleotide sequence of SEQ ID NO: 53.

[0255] In some embodiments, the rAAV vector genome further comprises a promoter operably linked to the Cas13 coding sequence.

[0256] In some embodiments, the promoter is a broad-spectrum promoter, a tissue-specific promoter, a cell-type-specific promoter, a constitutive promoter, or an inducible promoter; optionally, wherein the promoter comprises a promoter selected from the group consisting of: Cbh promoter, Cba promoter, pol I promoter, pol II promoter, pol III promoter, T7 promoter, U6 promoter, H1 promoter, retrovirus Rous sarcoma virus LTR promoter, cytomegalovirus (CMV) promoter, SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, elongation factor 1α short (EFS) promoter, β-glucuronidase (GUSB) promoter, cytomegalovirus (CMV) immediate early (Ie) enhancer and / or promoter, chicken β-actin (CBA) promoter or its derivatives such as CAG promoter, CB promoter, (human) elongation factor 1α-subunit (EF1α) promoter, ubiquitin C (UBC) promoter, prion promoter, neuron-specific enolase (NSE), neurofilament light chain (NFL) promoter, neurofilament heavy chain (NFH) promoter, Platelet-derived growth factor (PDGF) promoter, platelet-derived growth factor B chain (PDGF-β) promoter, synapsin (Syn) promoter, synapsin 1 (Syn1) promoter, methyl-CpG binding protein 2 (MeCP2) promoter, Ca2+ / calmodulin-dependent protein kinase II (CaMKII) promoter, metabotropic glutamate receptor 2 (mGluR2) promoter, neurofilament light chain (NFL) promoter, neurofilament heavy chain (NFH) promoter, β-globin minigene nβ2 promoter, preproenkephalin (PPE) promoter, enkephalin (Enk) promoter, excitatory amino acid transporter 2 (EAAT2) promoter, glial fibrillary acidic protein (GFAP) promoter, and myelin basic protein (MBP) promoter.

[0257] In some embodiments, the promoter comprises a Cbh promoter, such as a Cbh promoter having the polynucleotide sequence of SEQ ID NO:44.

[0258] In some embodiments, the promoter comprises a MECP2 promoter, such as the mouse MECP2 (mMECP2) promoter having the sequence of SEQ ID NO:63.

[0259] In some embodiments, the rAAV vector genome further comprises a polyadenylation (polyA) signal sequence, such as bovine growth hormone polyadenylation signal (bGH polyA), small polyA signal (SPA), human growth hormone polyadenylation signal (hGH polyA), SV40 polyA signal (SV40 polyA), rabbit beta globin polyA signal (rBG polyA), and functional truncations or variants thereof; or corresponding polyA sequences.

[0260] In some embodiments, the polyA signal sequence comprises a bovine growth hormone polyadenylation signal (bGHpolyA) or a variant thereof; optionally, the bGH polyA comprises the polynucleotide sequence of SEQ ID NO:48.

[0261] In some embodiments, the sgRNA coding sequence is operably linked to a promoter; optionally wherein the promoter is a broad-spectrum promoter, a tissue-specific promoter, a cell type-specific promoter, a constitutive promoter, or an inducible promoter; optionally selected from: Cbh promoter, Cba promoter, pol I promoter, pol II promoter, pol III promoter, T7 promoter, U6 promoter, H1 promoter, retroviral Rous sarcoma virus LTR promoter, cytomegalovirus (CMV) promoter, SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, elongation factor 1α short (EFS) promoter, β-glucuronidase (GUSB) promoter, cytomegalovirus (CMV) immediate early (Ie) enhancer and / or promoter, chicken β-actin (CBA) promoter or its derivatives such as CAG promoter, CB promoter, (human) elongation factor 1α-subunit (EF1α) promoter, ubiquitin C (UBC) promoter, prion promoter, neuron-specific enolase (NSE), neurofilament light chain (NFL) promoter, neurofilament heavy chain (NFH) promoter, platelet-derived growth factor The promoter comprises a PDGF (PDGF) promoter, a platelet-derived growth factor B chain (PDGF-β) promoter, a synapsin (Syn) promoter, a synapsin 1 (Syn1) promoter, a methyl-CpG binding protein 2 (MeCP2) promoter, a Ca2+ / calmodulin-dependent protein kinase II (CaMKII) promoter, a metabotropic glutamate receptor 2 (mGluR2) promoter, a neurofilament light chain (NFL) promoter, a neurofilament heavy chain (NFH) promoter, a β-globin minigene nβ2 promoter, a preproenkephalin (PPE) promoter, an enkephalin (Enk) promoter, an excitatory amino acid transporter 2 (EAAT2) promoter, a glial fibrillary acidic protein (GFAP) promoter, and a myelin basic protein (MBP) promoter; optionally, wherein the promoter is an RNA pol III promoter or a CMV promoter (such as SEQ ID NO: 50).

[0262] In some embodiments, the RNA pol III promoter is a U6 promoter (such as SEQ ID NO: 49), H1, 7SK, or a variant thereof.

[0263] In some embodiments, (1) the sgRNA comprises a spacer sequence directly linked to a DR sequence (e.g., SEQ ID NO: 6); (2) the sgRNA comprises a spacer sequence flanked by two DR sequences (e.g., each having SEQ ID NO: 6); or (3) the sgRNA comprises two or more spacer sequences; and wherein each spacer sequence is flanked by two DR sequences, each of which is capable of forming a complex with the Cas13 polypeptide; optionally, the sgRNA comprises two spacer sequences flanked by three DR sequences (e.g., each having SEQ ID NO: 6) to form a DR-spacer-DR-spacer-DR structure

[0264] Each of the spacer sequences is independently substantially complementary to a different target RNA sequence on the MECP2 mRNA, and each is capable of guiding the Cas13 polypeptide to cleave the corresponding different target RNA sequence.

[0265] In some embodiments, the DR sequence comprises (1) SEQ ID NO:6; (2) a sequence that is at least 90%, 92%, 94%, 95%, 96%, 98%, or 99% identical to SEQ ID NO:6; (3) a sequence that differs from SEQ ID NO:6 in at most 1, 2, 3, 4, or 5 nucleotides; or (4) a sequence that has a secondary structure substantially identical to SEQ ID NO:6.

[0266] In some embodiments, each of the DR sequences comprises, consists essentially of, or consists of SEQ ID NO:6.

[0267] In some embodiments, the target RNA sequence comprises a stretch of consecutive nucleotides of SEQ ID NO: 60; optionally 20-50, or 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 consecutive nucleotides of SEQ ID NO: 60, such as 30 consecutive nucleotides, such as any one of SEQ ID NOs: 27-36.

[0268] In some embodiments, the spacer sequence is independently selected from any one of SEQ ID NOs: 17-26 or a variant thereof, and the variant differs from any one of SEQ ID NOs: 17-26 by at most 1, 2, 3, 4, 5, or 6 nucleotides, and does not substantially diminish the ability of guiding the Cas13 polypeptide to bind to the sgRNA to form a Cas13-sgRNA complex targeting the target RNA sequence to cleave the target RNA.

[0269] In some embodiments, the MECP2 mRNA is associated with a disease or disorder, such as MECP2 Duplication Syndrome (MDS).

[0270] In some embodiments, the rAAV vector genome comprises an ITR to ITR polynucleotide (e.g., SEQ ID NO: 56, 57, or 66), wherein the ITR to ITR polynucleotide comprises, from 5' to 3':

[0271] (a) 5' ITR from AAV2 (e.g., SEQ ID NO: 52);

[0272] (b) U6 or CMV promoter (such as SEQ ID NO: 49 or 50);

[0273] (c) a first direct repeat (DR) DNA coding sequence encoding a first DR sequence (such as SEQ ID NO: 6);

[0274] (d) a first spacer coding sequence encoding a first spacer sequence specific to MECP2 mRNA (such as any one of SEQ ID NOs: 19-22 and 25);

[0275] (e) a second DR DNA coding sequence encoding a second DR (such as SEQ ID NO: 6);

[0276] (f) a second spacer coding sequence encoding a second spacer sequence specific for MECP2 mRNA (such as any one of SEQ ID NOs: 19-22 and 25);

[0277] (g) a third DR DNA coding sequence encoding the third DR (such as SEQ ID NO: 6);

[0278] (h) a Cbh promoter (e.g., a Cbh promoter comprising an enhancer sequence (e.g., SEQ ID NO: 45) and an intron sequence (e.g., SEQ ID NO: 46); optionally, the Cbh promoter comprises SEQ ID NO: 44);

[0279] (i) Kozak sequence (such as SEQ ID NO: 54);

[0280] (j) a first NLS encoding sequence (such as a sequence encoding SEQ ID NO: 47 or 58);

[0281] (k) a Cas13 polynucleotide encoding a Cas13 polypeptide of SEQ ID NO: 2, 4 or 61 excluding the first amino acid M (such as SEQ ID NO: 3, 5 or 62 excluding the start codon ATG);

[0282] (1) a second NLS encoding sequence (such as a sequence encoding SEQ ID NO: 47 or 58);

[0283] (m) an optional coding sequence encoding three tandem repeats of an HA tag sequence (e.g., SEQ ID NO: 55);

[0284] (n) a WPRE3 sequence (such as SEQ ID NO: 59);

[0285] (o) bGH polyA signal sequence (such as SEQ ID NO: 48); and

[0286] (p) 3' ITR from AAV2 (e.g., SEQ ID NO: 53);

[0287] or a polynucleotide that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% identical to said ITR to ITR polynucleotide;

[0288] Optionally, the ITR to ITR polynucleotide further comprises a linker sequence between any two adjacent (a)-(p) sequence elements;

[0289] Optionally, the sequence elements (b) to (g) that are 5' to the sequence elements (h) to (o) are relocated to be 3' to said sequence elements (h) to (o).

[0290] Another aspect of the invention provides a recombinant AAV (rAAV) vector genome comprising, consisting essentially of, or consisting of:

[0291] (1) SEQ ID NO: 56, 57 or 66, or a polynucleotide having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% identity thereto,

[0292] wherein the polynucleotide encoding

[0293] (a) a Cas13 polypeptide of SEQ ID NO: 2, 4 or 61, or

[0294] (b) a variant thereof having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 1 and having a non-conservative substitution at Y666 and / or Y677 of SEQ ID NO: 1 (e.g., a Y666A and / or Y677A substitution), wherein the variant has substantially the same (e.g., at least about 80%, 90%, 95%, 99% or more) guide RNA-specific nuclease activity as SEQ ID NO: 1 and substantially no (e.g., at most 20%, 15%, 10%, 5%) flanking (guide RNA-independent) nuclease activity of SEQ ID NO: 1; and

[0295] (2) an sgRNA coding sequence encoding an sgRNA, wherein the sgRNA comprises:

[0296] (A) a spacer sequence that is substantially complementary to a target RNA sequence of MECP2 mRNA; and

[0297] (B) a direct repeat (DR) sequence that forms a complex with the Cas13 polypeptide,

[0298] wherein when the sgRNA guides the Cas13 polypeptide to a target RNA sequence, the complex specifically cleaves MECP2 mRNA at or near the target RNA sequence, and has substantially the same (e.g., at least about 80%, 90%, 95%, 99% or more) guide RNA-specific nuclease activity as SEQ ID NO: 1, and substantially no (e.g., at most 20%, 15%, 10%, 5%) side-cutting (guide RNA-independent) nuclease activity as SEQ ID NO: 1;

[0299] Optionally, the sgRNA encoding sequence is 3' or 5' of the Cas13 encoding sequence.

[0300] In some embodiments, the rAAV vector genome is SEQ ID NO: 56, 57, or 66, or a polynucleotide at least 95% or 99% identical thereto.

[0301] Another aspect of the present invention provides a recombinant AAV (rAAV) viral particle comprising a rAAV vector genome as described herein.

[0302] In some embodiments, the rAAV virus particle comprises a capsid of a serotype of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV-DJ, or a member of the evolutionary branch to which any one of AAV PHP.eB, AAV1-AAV13 belongs, or a functional truncated variant or functional mutant thereof, which encapsidates the rAAV vector genome.

[0303] In some embodiments, the capsid serotype is AAV PHP.eB or AAV9.

[0304] Another aspect of the present invention provides a recombinant AAV (rAAV) viral particle comprising a rAAV vector genome as described herein encapsidated in a capsid of serotype AAV PHP.eB or AAV9.

[0305] Another aspect of the present invention provides a pharmaceutical composition comprising the rAAV vector genome as described herein, or the rAAV viral particle as described herein, and a pharmaceutically acceptable excipient.

[0306] Another aspect of the present invention provides a method for treating a disease or disorder associated with MECP2 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an rAAV vector genome as described herein, an rAAV viral particle as described herein, or a pharmaceutical composition as described herein, wherein the rAAV vector genome or the rAAV viral particle specifically downregulates the expression of the MECP2 that causes the disease or disorder.

[0307] In some embodiments, the administering comprises contacting the cell with the therapeutically effective amount of a rAAV vector genome as described herein, a rAAV viral particle as described herein, or a pharmaceutical composition as described herein.

[0308] In some embodiments, the cell is located in the CNS of the subject.

[0309] In some embodiments, the disease or disorder is MECP2 Duplication Syndrome (MDS).

[0310] In some embodiments, the administering comprises stereotactic or intracerebroventricular administration.

[0311] In some embodiments, the subject is a human.

[0312] In some embodiments, expression of MECP2 is reduced in the cell compared to a cell that has not been contacted with an rAAV vector genome as described herein, an rAAV viral particle as described herein, or a pharmaceutical composition as described herein.

[0313] In some embodiments, the expression of MECP2 in the subject is reduced by about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, or about 85% compared to the expression of MECP2 in the subject before administration.

[0314] Another aspect of the invention provides a guide RNA (gRNA) (e.g., a single guide RNA) comprising:

[0315] (A) a spacer sequence that is substantially complementary to a target RNA sequence of MECP2 mRNA; and

[0316] (B) Optionally, a direct repeat (DR) sequence capable of forming a complex with a Cas13 polypeptide, wherein when the sgRNA guides the Cas13 polypeptide to the target RNA sequence, the complex specifically cleaves the MECP2 mRNA at or near the target RNA sequence.

[0317] In some embodiments, the target RNA sequence comprises a stretch of consecutive nucleotides of SEQ ID NO: 60; optionally 20-50, or 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 consecutive nucleotides of SEQ ID NO: 60, such as 30 consecutive nucleotides, such as any one of SEQ ID NOs: 27-36.

[0318] In some embodiments, the gRNA comprises two or more identical or different spacer sequences, each spacer sequence flanked by two of the DR sequences.

[0319] In some embodiments, the gRNA comprises two different spacer sequences (e.g., Spacer 1 and Spacer 2) that separate three of the DR sequences (e.g., DR-Spacer 1-DR-Spacer 2-DR).

[0320] In some embodiments, the gRNA comprises one or more spacer sequences, each spacer sequence is independently selected from any one of SEQ ID NOs: 17-26 or a variant thereof, and the variant differs from any one of SEQ ID NOs: 17-26 by at most 1, 2, 3, 4, 5, or 6 nucleotides, and does not substantially diminish the ability to guide the Cas13 polypeptide to bind to the sgRNA to form a Cas13-sgRNA complex targeting the corresponding target sequence to cleave the target sequence.

[0321] In some embodiments, the DR sequence comprises (1) SEQ ID NO:6; (2) a sequence that is at least 90%, 92%, 94%, 95%, 96%, 98%, or 99% identical to SEQ ID NO:6; (3) a sequence that differs from SEQ ID NO:6 in at most 1, 2, 3, 4, or 5 nucleotides; or (4) a sequence that has a secondary structure substantially identical to SEQ ID NO:6.

[0322] In some embodiments, the Cas13 polypeptide comprises

[0323] (a) the amino acid sequence of SEQ ID NO: 2, 4 or 61, or

[0324] (b) a variant thereof having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 1 and a non-conservative substitution at Y666 and / or Y677 of SEQ ID NO: 1 (e.g., Y666A and / or Y677A substitution), wherein the variant has substantially the same (e.g., at least about 80%, 90%, 95%, 99% or more) guide RNA-specific nuclease activity as SEQ ID NO: 1 and substantially no (e.g., at most 20%, 15%, 10%, 5%) flanking (guide RNA-independent) nuclease activity of SEQ ID NO: 1.

[0325] Another aspect of the present invention provides a cell or its progeny, comprising an AAV vector genome as described herein, an rAAV viral particle as described herein, or a gRNA as described herein.

[0326] Another aspect of the present invention provides a kit comprising an AAV vector genome as described herein, an rAAV viral particle as described herein, a gRNA as described herein, or a cell as described herein or its progeny.

[0327] Another aspect of the present invention provides a method for preparing an rAAV particle as described herein, the method comprising:

[0328] a) introducing a nucleic acid encoding a rAAV vector genome as described herein or an RNA sequence transcribed therefrom, and a coding sequence for an AAV capsid as described herein into an AAV packaging system for a period of time sufficient to package the rAAV vector genome or the transcribed RNA into the AAV capsid to produce the rAAV particles, and

[0329] b) harvesting the rAAV particles; and optionally,

[0330] c) Isolating or purifying the harvested rAAV particles.

[0331] Example

[0332] The following examples are provided to further illustrate some embodiments of the present disclosure but are not intended to limit the scope of the invention; by their exemplary nature it will be understood that other procedures, methods or techniques known to those skilled in the art may alternatively be used.

[0333] Example 1 CRISPR-hfCas13f v2 system efficiently knocks down MECP2 expression in vitro

[0334] This example demonstrates the high in vitro knockdown efficiency of MECP2 expression by the CRISPR-hfCas13f v2 system of the present invention.

[0335] Plasmid construction:

[0336] The CRISPR-hfCas13f v2 system of the present invention comprises an hfCas13f v2 protein (SEQ ID NO: 2, Cas13f.1-Y666A, Y677A mutant) and an sgRNA targeting MECP2 (hereinafter referred to as "sgRNA [MECP2] 1-10" or "sg1-10" (SEQ ID NO: SEQ ID NO: 7-16)), wherein the sgRNA comprises two direct repeat sequences (each having SEQ ID NO: 6) and a target sequence targeting MECP2 mRNA (one of target RNA sequences 1-10 (SEQ ID NO: 27-36)) (one of spacers 1-10 (SEQ ID NO: 17-26)). As a negative control, a non-targeting sgRNA (hereinafter referred to as "sgRNA[NT]" or "NT", SEQ ID NO: 41) containing two direct repeat sequences (each having SEQ ID NO: 6) and a non-targeting spacer (SEQ ID NO: 42) was used instead of sgRNA[MECP2].

[0337] hfCas13f v2 protein (SEQ ID NO: 2) and sgRNA [MECP2] (SEQ ID NO: 7-16) or sgRNA [NT] (SEQ ID NO: 41) were encoded into the same plasmid together with the mCherry reporter (SEQ ID NO: 51) to form a treatment plasmid or a control plasmid, as shown in Figure 1A and 1B shown.

[0338] Spacers were also used in combination. The hfCas13f v2 protein (SEQ ID NO: 2) and sgRNA [MECP2] containing two spacers (9&3, 9&4, 9&5 or 9&6, SEQ ID NO: 37-40) were encoded into the same plasmid construct along with the mCherry reporter (SEQ ID NO: 51), as shown in FIG. Figure 1C shown.

[0339] Plasmid transfection:

[0340] HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin / streptomycin and maintained at 37°C and 5% CO2. The cultured cells were then seeded onto 6-well plates (1.0-1.2E+6 cells / well) and transfected with 3 μg of the treated or control plasmid using polyethyleneimine (PEI) transfection reagent. Two days after transfection, mCherry-positive transfected cells were sorted by flow cytometry for RNA extraction.

[0341] Cos-7 cells, an African green monkey kidney fibroblast-like cell line used as a typical target model cell for studying the MECP2 gene, were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin / streptomycin and maintained at 37°C and 5% CO2. The cultured cells were then seeded onto 6-well plates (1.0-1.2E+6 cells / well) and transfected with 3 μg of treated or control plasmid using polyethyleneimine (PEI) transfection reagent. Two days after transfection, mCherry-positive transfected cells were sorted using flow cytometry for RNA extraction.

[0342] RT-qPCR detection:

[0343] Total RNA from RNA extraction was first purified using Trizol (Ambion) and then reverse transcribed into complementary DNA (HiScript Q RT SuperMix for qPCR, Vazyme Biotech) for RT-qPCR detection. RT-qPCR reactions were followed by SYBR green (AceQ qPCR SYBR Green premix, Vazyme Biotech). MECP2 mRNA transcript levels were measured and normalized to the mRNA level of the housekeeping gene ACTIN using MECP2 primers and hACTIN primers.

[0344] result:

[0345] To determine whether the CRISPR-hfCas13f v2 system could be used to knock down MECP2 gene expression, we designed 10 single-guide (sg) RNAs targeting MECP2 mRNA (with homology in human, mouse, and monkey).

[0346] In the case of using a single spacer, the CRISPR-hfCas13f v2 system targeting MECP2 with sg3, 4, 5, 6, and 9 reduced MECP2 mRNA levels by >60% compared to the negative control ( Figure 2A and Table 1 ).

[0347] In the case of dual spacers, the CRISPR-hfCas13f v2 system targeting MECP2 with paired spacers 9&3, 9&4, 9&5, and 9&6 reduced MECP2 mRNA levels by >80% relative to the negative control in 293T cells ( Figure 2B and Table 2), where the best 97.42% was achieved using sgRNA9&3, and the MECP2 mRNA level was reduced by > approximately 55% relative to the negative control in Cos7 cells ( Figure 2C and Table 3), where the best 69.23% was achieved using sgRNA9&3.

[0348] All these results indicate the great potential of the MECP2-targeting CRISPR-hfCas13f v2 system of the present invention for treating MECP2-related diseases.

[0349] Table 1. Reduction of MECP2 mRNA levels by each sgRNA in 293T cells

[0350]

[0351] Table 2. Reduced MECP2 mRNA levels in 293T cells by sgRNAs harboring double spacers

[0352]

[0353] Table 3. Reduction of MECP2 mRNA levels by sgRNAs with dual sgRNAs in Cos7 cells

[0354]

[0355] Example 2 CRISPR-hfCas13f v2 system efficiently knocks down MECP2 expression in vivo

[0356] In order to demonstrate the in vivo editing efficiency of the CRISPR-hfCas13f v2 system of the present invention in Example 1, the system was delivered to the target cells of animals in vivo using the AAV.PHP.eB delivery system.

[0357] AAV.PHP.eB transgenic plasmid construction:

[0358] Similar to the treatment plasmid in Example 1, a treatment transgenic plasmid encoding hfCas13f v2 and sgRNA [MECP2] 9 & 3 for AAV.PHP.eB packaging was constructed, as shown in Figure 3A shown.

[0359] Preparation of recombinant AAV.PHP.eB particles:

[0360] The treated AAV.PHP.eB particles herein were produced by co-transfecting the corresponding transgenic plasmid, packaging plasmid, and helper plasmid into HEK293T cells at a weight ratio of 1:1:2 using a conventional triple plasmid transfection system. The transgenic plasmid was packaged by the AAV.PHP.eB capsid to form a genome within the capsid, and the genome and the capsid together constituted the AAV.PHP.eB particle.

[0361] Specifically, HEK293T cells were cultured in competent DMEM medium and plated 24 hours before plasmid transfection. Shortly before transfection, the medium was replaced with fresh DMEM containing 2% FBS. PEI-MAX was used as a transfection reagent. Transfected HEK293T cells were harvested from the culture medium 72 hours after translation. Treated AAV.PHP.eB particles were purified from the cells by iodixanol density gradient ultracentrifugation.

[0362] RT-qPCR was used with a pair of hfCas13f v2 primers specific for the hfCas13f v2 sequence on the genome to detect the genomic titer of any genome packaged in the processed AAV.PHP.eB particles.

[0363] Mice:

[0364] C57BL / 6 mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. All experimental protocols were approved by the Animal Care and Use Committee of the Institute of Neuroscience, Chinese Academy of Sciences, Shanghai, China and HUIGENE THERAPEUTICS CO., LTD.

[0365] Unilateral stereotactic injection into the dentate gyrus (DG) region of the hippocampus (hip) of C57BL / 6 mice to verify the knockdown effect in vivo:

[0366] Eight-week-old C57BL / 6 mice were anesthetized with a mixture of zotir (60 μg / g) and xylazine (10 μg / g) and then stereotaxically injected unilaterally in the Hip DG region with 500 nl of AAV.PHP.eB injection ( Figure 3B ), where the dose was 5E+8 vg / mouse (1E+13 vg / mL) (x=-1.15, y=-1.7, and z=-2.15).

[0367] RT-qPCR detection:

[0368] Three weeks after injection, mice were anesthetized and perfused with PBS, and Hip tissues from C57BL / 6 mice were harvested. Total Hip RNA was extracted and purified using Trizol (Ambion), then reverse-transcribed into complementary DNA (HiScript Q RTSuperMix for qPCR, Novazon Biotech) for RT-qPCR. mMECP2 RNA levels were detected by RT-qPCR using a SYBR green probe (AceQ qPCRSYBR Green Master Mix, Novazon Biotech), and normalized to the level of housekeeping gene mACTIN mRNA using MECP2 primers and mACTIN primers.

[0369] Immunofluorescence (IF) detection:

[0370] Three weeks after injection, mice were anesthetized and perfused with PBS solution followed by 4% paraformaldehyde (PFA) solution. The whole brain of the mouse was harvested and fixed in 4% PFA solution. After 8 hours, the brain was washed with PBS and dehydrated with 30% sucrose until the tissue was completely covered. The brain was embedded in OCT culture medium (SAKURA) and cut into 35 μm thick sections using a cryostat.

[0371] Brain sections were washed with PBS for 5 min, incubated at 70°C in 0.01 M citrate buffer at pH 6 for 30 min, and then cooled at RT for 30 min, blocked with blocking solution for 1 h, and then incubated overnight in primary antibody solution at 4°C. Primary antibodies against the following antigens were used: MECP2 (1:1,000; CST, catalog number 3456s). Further incubation with secondary antibodies (Alexa 647 conjugated; 1:1,000; Thermo Scientific) was performed at RT for 2 h to detect the primary antibodies, followed by nuclear counterstaining with DAPI (Invitrogen; catalog number P36931). Fluorescent confocal sections were observed using a Nikon C2+ confocal microscope. Images were analyzed using Image J.

[0372] result:

[0373] Compared with the uninjected side of the same Hip as a negative control, the in vivo knockdown efficiency of the CRISPR-hfCas13f v2 system of the present invention with sg9&3 was 22.4% for MECP2 mRNA ( Figure 3C ) and 37.9% for MECP2 protein ( Figure 3D and 3E ), indicating its high efficacy in treating MeCP2-related diseases in Hip.

[0374] Example 3 CRISPR-hfCas13f v2.5 system efficiently knocks down MECP2 expression in vivo

[0375] In order to demonstrate the in vivo editing efficiency of the CRISPR-hfCas13f v2.5 system of the present invention, the system was delivered to the target cells of animals in vivo using the AAV.PHP.eB delivery system. The CRISPR-hfCas13f v2.5 system differs from the CRISPR-hfCas13f v2 system in Examples 1 and 2 in that hgCas13f v2.5 (SEQ ID NO: 4, Cas13f.1-L641A, Y666A, Y677A mutant) is used instead of hfCas13f v2 (SEQ ID NO: 2, Cas13f.1-Y666A, Y677A mutant).

[0376] AAV.PHP.eB transgenic plasmid construction:

[0377] Similar to the treatment plasmids and control plasmids in Example 1, treatment and control transgenic plasmids encoding hfCas13f v2.5 and sgRNA [MECP2] 9&3 or sgRNA [NT] for AAV.PHP.eB packaging were constructed, as shown in Figure 4A and 5D shown.

[0378] Preparation of recombinant AAV.PHP.eB particles:

[0379] Comparatively, using a conventional triple plasmid transfection system, the treated and control AAV.PHP.eB particles herein were produced by co-transfecting the corresponding transgenic plasmid, packaging plasmid, and helper plasmid into HEK293T cells at a weight ratio of 1:1:2. The transgenic plasmid was packaged by the AAV.PHP.eB capsid to form a genome within the capsid, and the genome and the capsid together constituted the AAV.PHP.eB particle.

[0380] Specifically, HEK293T cells were cultured in competent DMEM medium and plated 24 hours prior to plasmid transfection. Shortly before transfection, the medium was replaced with fresh DMEM containing 2% FBS. PEI-MAX was used as a transfection reagent. Transfected HEK293T cells were harvested from the culture medium 72 hours after translation. Treatment and control AAV.PHP.eB particles were purified from the cells by iodixanol density gradient ultracentrifugation.

[0381] RT-qPCR was used with the same hfCas13f v2 primer pair as in Example 2, specific for the hfCas13f v2.5 sequence on the genome, to detect the genomic titer of any genome packaged in treatment and control AAV.PHP.eB particles.

[0382] Mice:

[0383] C57BL / 6 mice were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd., and FVB / N-Tg(MECP2 / EGFP)1Hzo / J (MDS) mice were purchased from Jackson Laboratory (Jax Lab) and housed in an in-house animal facility with a 12h:12h light / dark cycle, with free access to food and water. P0-P2 (postnatal day 0-2) MDS mice were generated by crossing FVB / N-Tg(MECP2 / EGFP)1Hzo / J mice, and genotypes were determined by PCR using MDS genotype test primers and positive control primers. All experimental protocols were approved by the Animal Care and Use Committee of the Institute of Neuroscience, Chinese Academy of Sciences, Shanghai, China, and Huida (Shanghai) Biotechnology Co., Ltd.

[0384] Unilateral stereotactic injection into the dentate gyrus (DG) region of the hippocampus (hip) of C57BL / 6 mice to verify the knockdown effect in vivo:

[0385] Eight-week-old C57BL / 6 mice were anesthetized with a mixture of zotir (60 μg / g) and xylazine (10 μg / g), and then unilaterally stereotaxically injected with 500 nl of AAV-PHP.eB in the Hip DG region ( Figure 4B ), with different doses of 5E+8, 2.5E+8 or 1.25E+8 vg / mouse (x=-1.15, y=-1.7 and z=-2.15).

[0386] Intracerebroventricular (ICV) administration into the brain of MDS mice for treatment:

[0387] P2 MDS mice were anesthetized on ice for 3 minutes. After pupil dilation, a small hole was punctured just posterior to the corneal limbus using a sterile 31G 1 / 2 needle. 4 μL of treatment or control AAV.PHP.eB at a dose of 1E+13 vg / mL (4E+10 vg / mouse) was injected through the hole using a Hamilton syringe with a 33G blunt needle.

[0388] RT-qPCR detection:

[0389] Three weeks after injection, mice were anesthetized and perfused with PBS, and Hip tissue was harvested from C57BL / 6 mice. Total Hip RNA was extracted and purified using Trizol (Ambion), then reverse-transcribed into complementary DNA (HiScript Q RT SuperMix for qPCR, Novazon Biotech) for RT-qPCR. mMECP2 RNA levels were detected by RT-qPCR using a SYBR green probe (AceQ qPCR SYBR Green Master Mix, Novazon Biotech), and normalized to the level of housekeeping gene mACTIN mRNA using primers for MECP2 and mACTIN.

[0390] Western blot detection:

[0391] 3 weeks after injection, mice were anesthetized and perfused with PBS, and the prefrontal cortex (PFC), hip, striatum (CPU), hypothalamus (Hyp), olfactory bulb (OB) and cerebellum (CB) tissues of C57BL / 6 mice and MDS mice were harvested. The total protein of the above tissues was extracted with RIPA lysis buffer (Beyotime; Catalog No. P0013B), and the protein concentration was determined using bicinchoninic acid (BCA) method (Thermo Fisher; Catalog No. 23225). The total protein of an equal amount (20 μg) of each sample was separated by 4%-20% SDS-polyacrylamide gel electrophoresis, and each aliquot was then transferred to Immobilon-PSQ transfer membrane (Millipore; Catalog No. ISEQ00010). At room temperature (RT), the membrane was incubated in blocking solution (5% skim milk powder in TBS) for 1 h. The cells were incubated with primary antibodies [including antibodies against MECP2 (1:500; CST, catalog number 3456s), HA (1:500; CST; catalog number 3724), and GAPDH (1:1,000; Proteintech; catalog number 60004-1-Ig), as a loading control] at 4°C overnight. Further incubation with secondary antibodies (anti-rabbit IgG HRP-linked antibody and anti-mouse IgG HRP-linked antibody, CST, catalog number 7074S and 7076S, diluted 1:3,000 in TBST buffer) was performed at RT to detect the primary antibodies for 1-2 hours. Images were captured using ECL (Biyuntian; catalog number P0018AS). The gray value of MECP2 was quantified by using ImageJ, and the relative expression level of MECP2 was estimated as the gray value of MECP2 / the gray value of the loading control GAPDH.

[0392] Immunofluorescence (IF) detection:

[0393] Three weeks after injection, mice were anesthetized and perfused with 4% paraformaldehyde (PFA) solution. The whole brains of the mice were harvested and fixed in 4% PFA solution. After 8 h, the brains were washed with PBS and dehydrated with 30% sucrose until the tissue was completely covered. The brains were embedded in OCT culture medium (SAKURA) and cut into 35 μm thick sections using a cryostat.

[0394] Brain sections were washed with PBS for 5 min, incubated at 70°C in 0.01 M citrate buffer at pH 6 for 30 min, and then cooled at RT for 30 min, blocked with blocking solution for 1 h, and then incubated overnight in primary antibody solution at 4°C. Primary antibodies against the following antigens were used: MECP2 (1:1,000; CST, catalog number 3456s), HA (1:500; Roche, catalog number 11867423001), and NeuN (1:1,000; CST, catalog number 24307s). Further incubation with secondary antibodies (Alexa 546- and 647-conjugated; 1:1,000; Thermo Scientific) was performed at RT for 2 h to detect the primary antibodies, followed by nuclear counterstaining with DAPI (Invitrogen; catalog number P36931). Fluorescent confocal sections were observed using a Nikon C2+ confocal microscope. Images were analyzed using Image J.

[0395] Behavioral testing:

[0396] All data collection and analysis were performed by individuals blinded to genotype and treatment. All behavioral studies were performed during the light period. Mice were acclimated to the testing room for 1 h before each test. At least one day was allowed between assays for mouse recovery.

[0397] Accelerating Rotarod Test. After acclimation to the testing room, motor coordination was measured using an accelerating rotarod apparatus (Ugo Basile). Mice were tested on two consecutive days, with three trials each, and a 60-minute interval between trials and rest. Each trial lasted a maximum of 10 minutes, with the rotarod accelerating from 4 to 40 rpm within the first 5 minutes. The time it took for each mouse to fall from the rotarod (fall latency) was recorded.

[0398] Open field test. After acclimation to the test room, mice were placed in the center of an open field (40 × 40 × 30 cm) and their behavior was tracked by laser beam breaks for 10 min. General locomotor activity was automatically analyzed using EthoVision XT software (Noldus). In addition, rearing activity, time spent in the center of the field, and entries into the center were also analyzed.

[0399] Elevated plus maze test. After acclimation in the test room, mice were placed in the center of the maze facing one of the two open arms. The mouse behavior was video-tracked for 10 min, and EthoVision XT software (Noldus) was used to record and analyze the time mice spent in the open arms, the distance they entered the open arms, and the distance they traveled in the open arms.

[0400] Three-chamber test. Age- and sex-matched C57Bl / 6 mice were used as new companions. Two days before the test, the new companion mice were adapted to a wire cup (3 inches in diameter × 4 inches high) for 1 hour every day. After adapting in the test chamber, the mice were placed in the center chamber and allowed to explore the three chambers for 10 minutes. Next, the new companion mice were placed in the wire cup in the left or right chamber. Inanimate objects were placed in the wire cup of the opposite chamber as controls. The position of the new mice was randomized between the left and right chambers in the subjects to control side preference. The mice tested were allowed to explore another 10 minutes again. The time spent studying the new companion (defined by feeding, sniffing, or scratching at the wire cup) and the time spent studying the inanimate objects were analyzed and recorded using EthoVision XT software (Noldus).

[0401] result:

[0402] In the case of unilateral stereotactic injection of AAV.PHP.eB particles into the Hip DG region of C57BL / 6 mice, the in vivo knockdown efficiency of the CRISPR-hfCas13f v2.5 system of the present invention with sg9&3 was 78.1% (5E+8 vg / mouse), 70.6% (2.5E+8 vg / mouse), and 11.8% (1.25E+8 vg / mouse) for MECP2 mRNA, compared to the uninjected side of the same Hip as a negative control. Figure 4C ) and for MECP2 protein were 36.4% (5E+8 vg / mouse), 31.7% (2.5E+8 vg / mouse), and 33.7% (1.25E+8 vg / mouse) ( Figure 4D and 4E ), indicating its high efficacy in treating MeCP2-related diseases in Hip.

[0403] RT-qPCR results of hfCas13f v2.5 ( Figure 5A ) and IF of the HA-tag in the AAV vector genome ( Figure 5B ) and WB( Figure 5C) The results showed that ICV administration of AAV.PHP.eB particles successfully delivered the AAV vector genome to the whole brain of MDS mice and successfully expressed hfCas13f v2.5. Compared with the negative control of ICV injection of control AAV.PHP.eB particles in the whole brain, at a dose of 4E+10 vg / mouse, the in vivo knockdown efficiency of MECP2 protein by the CRISPR-hfCas13f v2.5 system of the present invention was approximately 67% in Hip, 62% in CPU, 55% in OB, and 15% in PFC ( Figure 6A 、 6B and 6C), indicating high efficacy in treating MECP2-related diseases in the whole brain.

[0404] The behavior of MDS mice injected with AAV.PHP.eB particles was evaluated separately at week 4 in the accelerating rotarod test, week 7 in the elevated plus maze test, and week 10 in the accelerating rotarod test, open field test, elevated plus maze test, and three-chamber test after ICV administration. The results showed that the abnormal motor behavior in the accelerating rotarod test of MDS mice was partially reversed at week 4 after AAV ICV administration ( Figure 7A ), the anxiety-like behavior in the elevated plus maze test of MDS mice was partially reversed 7 weeks after AAV ICV administration ( Figure 7B At 10 weeks after AAV ICV administration, abnormal movements in the accelerating rotarod test, anxiety-like behaviors in the open field test and elevated plus maze test, and social behaviors in the three-chamber test of MDS mice were almost completely reversed ( Figures 8A-8D ), indicating that the abnormal behavior of MDS mice was rescued by the CRISPR-hfCas13f v2.5 system of the present invention.

[0405] The toxicity of AAV.PHP.eB particles was assessed using NeuN IF at week 7 after ICV administration. The results showed that the NeuN positive signal in the whole brain of the MDS mice administered with ICV was similar to that of the negative control MDS mice without ICV administration ( Figure 9 ), indicating that no toxicity was observed at week 7 after ICV administration.

[0406] In summary, the data provided in this article demonstrate that the CRISPR-hfCas13f v2 and v2.5 systems of the present invention efficiently reduce the expression of MECP2 in cultured 293T cells and Cos7 cells in vitro and in mouse hip and whole brain in vivo, and that ICV administration of AAV.PHP.eB particles delivering the hfCas13f v2.5-double-sgRNA[MECP2] system can rescue the abnormal behavior of MDS mice, showing good prospects for the treatment of MDS and other MECP2-related diseases in humans.

[0407] Example 4. In vivo knockdown of human MECP2 mRNA by the CRISPR-Cas13 system containing hfCas13f.v v3

[0408] This example demonstrates the in vivo knockdown efficiency of rAAV9 particles delivering a CRISPR-Cas13 system containing hfCas13f.1v3 (SEQ ID NO: 61) and sg9&3.

[0409] In vitro fluorescent reporter experiments revealed that hfCas13f.1v3 achieved significantly higher cleavage activity and significantly lower paracleavage activity than hfCas13f.1v2, and thus hfCas13f.1v3 was used to replace hfCas13f.1v2 ( Figure 12 ).

[0410] In addition, the knockdown efficiency of MECP2 and the specificity of Cas13f-gMECP2 were examined. Plasmids containing different versions of Cas13f.1 protein were transfected into 293T cells together with sg9 and sg3 of MECP2. qPCR and Western blotting results showed that among the different versions of Cas13f.1, hfCas13f.1v3 exhibited the highest MECP2 knockdown efficiency ( Figure 13 and 14 Whole transcriptome sequencing (RNA-seq) results showed that hfCas13f.1v3 induced the lowest number of differentiation genes, and most of these genes were MECP2-related genes, indicating that hfCas13f.1v3 has high specificity in targeting MECP2 with sg9 and sg3 ( Figure 15 ).

[0411] Transgenic plasmid construction:

[0412] The rAAV transgenic plasmids used for packaging into AAV9 capsids to prepare integrated rAAV9 particles were designed to contain the elements in Table 4 below from 5' to 3'. The transgenic plasmids can encode one guide nucleic acid under the control of a promoter or two, three or more guide nucleic acids under the control of the same promoter or separate promoters.

[0413] Table 4. Elements of rAAV transgenic plasmids

[0414]

[0415]

[0416] The ITR to ITR sequence of the vector genome of the rAAV9 particle is shown in SEQ ID NO: 66. The rAAV9 vector genome may also encode an HA tag for observing distribution.

[0417] rAAV9 particles were prepared and administered similarly as described above, except that serotype AAV9 was used instead of serotype AAV-PHP.eB. mRNA and protein levels were measured similarly as described above.

[0418] result:

[0419] rAAV9 particles were administered into the brains of P1 MDS mice by ICV injection. After 12 weeks, the expression of hfCas13f.1v3 in the whole brain was detected by IF staining of HA. hfCas13f.1v3 was widely distributed in the brain. Then, the knockdown efficiency of MeCP2 in the cortex was tested by co-staining of HA and MeCP2, in which MeCP2 TG mice, Mecp2 + / y Mice and Mecp2 - / y IF results showed that the HA-tag was widely distributed in the cortex, and the expression of MeCP2 in HA-positive cells was significantly lower than that in the control MeCP2 TG mice and slightly higher than that in the Mecp2 + / y These results indicate that AAV9-mediated hfCas13f.1v3-gMECP2 editing effectively knocks down MeCP2 in the whole brain of MECP2 TG mice.

[0420] To ensure the safety of AAV9-hfCas13f.1v3-gMECP2 for MDS treatment and clinical application, the HA tag in the construct was removed. To explore the optimal dose of rAAV9-hfCas13f.1v3-gMECP2 in humanized MECP2 TG mice, P1 MECP2 TG mice were treated with different doses of rAAV (4.5E8 vg / mouse to 4.5E10 vg / mouse) via ICV injection, followed by a series of tests to evaluate its efficacy in MECP2 TG mice. Four weeks after injection, the transduction efficiency of rAAV9-hfCas13f.1v3-gMECP2 was detected in the whole brain by absolute quantitative PCR.

[0421] The results showed that hfCas13f.1v3 was widely expressed in the whole brain of MECP2 TG mice treated with rAAV9-hfCas13f.1v3-gMECP2 (Figure S4B). Four weeks later, the expression of hfCas13f.1v3, gRNA and MECP2 in brain regions closely related to MDS (such as the cortex, striatum and hippocampus) was analyzed by qPCR. The results showed that the amount of rAAV9-hfCas13f.1v3-gMECP2 increased in a dose-dependent manner. In addition, the expression levels of hfCas13f.1v3 and gRNA in the hippocampus were lower than their expression levels in the cortex and striatum. For the expression of MECP2, the expression of MeCP2 (representing mouse Mecp2 and MECP2 genes) and GFP (representing the human MECP2 gene, in MECP2 TG mice, GFP was fused to the C-terminus of human MECP2) was analyzed. The results showed that after rAAV9-hfCas13f.1v3-gMECP2 treatment, the expression of MeCP2 and GFP was dose-dependently reduced in the cortex, striatum, and hippocampus. For the cortex, the lowest effective dose that could effectively knock down the mRNA and protein of MECP2 in MECP2 TG mice was dose 2. In the striatum and hippocampus, the effective dose was dose 4. The highest dose (dose 5) normalized the expression of MECP2 in the cortex and striatum. In addition, the expression of human MeCP2 protein with GFP antibody in the cortex of MECP2 TG mice treated with the highest dose of rAAV9-hfCas13f.1v3-gMECP2 was examined by Western blotting. The results showed that the protein level of human MeCP2 in the rAAV9-hfCas13f.1v3-gMECP2-treated group was reduced by approximately 60% compared with MDS mice. Therefore, the results indicate that human MECP2 can be effectively knocked down by rAAV9-hfCas13f.1v3-gMECP2. In addition, IF results showed that MeCP2 was normalized in the cortex, striatum, CA1, and DG regions of MECP2 TG mice 12 weeks after ICV injection of rAAV9-hfCas13f.1v3-gMECP2.

[0422] To test whether normalizing MeCP2 expression could reverse the impaired behavioral phenotype of MECP2 TG mice, behavioral tests were performed in MECP2 TG mice 8 weeks after administration of different doses of rAAV9-hfCas13f.1v3-gMECP2 (dose 4 and dose 5). The accelerating rotarod test showed that the prolonged latency to fall from the rotating rod was reduced in rAAV9-hfCas13f.1v3-gMECP2-treated MECP2 TG mice at both doses. In addition, the open field test showed that MECP2 TG mice exhibited reduced exploratory behavior, which could be improved by treatment with rAAV9-hfCas13f.1v3-gMECP2 at dose 5. In addition, the elevated plus maze test showed that the MeCP2 TG mice exhibited reduced exploratory behavior, which could be improved by treatment with rAAV9-hfCas13f.1v3-gMECP2 at dose 5. + / y Compared with mice, MECP2 TG mice showed increased anxiety-like behavior, which could be greatly alleviated by administering rAAV9-hfCas13f.1v3-gMECP2 at two doses. In the three-chamber social test, MECP2 TG mice showed less communication behavior, which could be greatly improved by treatment with two doses of rAAV9-hfCas13f.1v3-gMECP2. In addition, the expression of dysregulated genes in MDS, such as Aw551984, Npbwr1, Crh, Efemp1, Oprk1, and Tsc22d3 (Carvalho et al., 2009; Samaco et al., 2012), was also examined. qPCR results revealed that the above genes were partially or completely normalized by administering rAAV9-hfCas13f.1v3-gMECP2. In addition, RNA-seq was performed on cortical tissue four weeks after ICV injection of AAV9-hfCas13f.1v3-gMECP2. Results showed that aberrant gene expression in male MECP2 TG mice was largely rescued by hfCas13f.1v3-gMECP2 treatment.

[0423] To test the long-term therapeutic effects of rAAV9-hfCas13f.1v3-gMECP2, behavioral tests were performed in Mecp2 TG mice 26 weeks after rAAV9-hfCas13f.1v3-gMECP2 administration. The open field test showed that Mecp2 TG mice exhibited reduced exploratory behavior, which could be improved by long-term rAAV9-hfCas13f.1v3-gMECP2 treatment. In addition, the elevated plus maze test showed that Mecp2 TG mice exhibited reduced exploratory behavior compared to Mecp2 + / yCompared with mice, anxiety-like behavior in MECP2TG mice was increased, and anxiety-like behavior could be greatly alleviated by long-term administration of rAAV9-hfCas13f.1v3-gMECP2. Interestingly, the median lifespan of MECP2TG mice injected with AAV9-hfCas13f.1v3-gMECP2 was significantly increased compared with littermates injected with PBS (156+-10.56 days). Five of six MECP2TG mice treated with AAV9-hfCas13f.1v3-gMECP2 survived for more than 220 days, while only one of ten MECP2TG mice treated with PBS survived for more than 220 days. Therefore, a single administration of AAV9-hfCas13f.1v3-gMECP2 into the central nervous system is sufficient to greatly prolong the survival of MECP2TG mice.

[0424] Studies have shown that AAV may cause toxic effects and long-term immunogenicity. Therefore, the concentrations of neurofilament light chain (NFL, neuronal / axonal damage biomarker), ALT and AST (liver damage biomarkers), BUN (kidney damage biomarker) and interferon-γ (IFN-γ, immunogenic factor) in the serum of MECP2 TG mice treated with rAAV9-hfCas13f.1v3-gMECP2 were detected by ELISA analysis after 12 weeks, and no significant changes were found. The above results reveal that there is almost no neuronal / axonal damage or immunogenic effect in rAAV9-hfCas13f.1v3-gMECP2 treatment of MECP2 TG mice.

[0425] In addition, P1MECP2TG mice were treated with a dose of 3.36E10 vg of rAAV9-hfCas13f.1v3-gMECP2 via IT injection. It was found that hfCas13f.1v3 was mainly expressed in the spine. The distribution of hfCas13f.1v3 in the brainstem, cerebellum and brain was very limited, and the expression of MECP2 in these regions did not change significantly. These results suggest that ICV injection of AAV9-hfCas13f.1v3-gMECP2 may be a better strategy for the treatment of MDS compared with IT injection.

[0426] Eight-week-old male MECP2 TG mice were also treated with rAAV9-hfCas13f.1v3-gMECP2 via ICV injection. hfCas13f.1v3 and MECP2 sgRNA were found to be widely expressed in the cortex, striatum, and hippocampus 4 weeks after injection, and the mRNA level of MECP2 in rAAV9-hfCas13f.1v3-gMECP2-treated MECP2 TG mice was significantly reduced compared with that in control MECP2 TG mice, but still higher than that in MeCP2 + / y Levels in mice. Western blot results showed that the total protein level of MeCP2 was slightly reduced in MECP2 TG mice treated with rAAV9-hfCas13f.1v3-gMECP2 compared with MECP2 TG mice, and human MeCP2 (GFP) protein was significantly reduced in MECP2 TG mice treated with rAAV9-hfCas13f.1v3-gMECP2 compared with MECP2 TG mice. Eight weeks after administration of rAAV9-hfCas13f.1v3-gMECP2, some abnormal behavioral phenotypes of MECP2 TG mice (including prolonged latency to fall and exploratory behavior) were rescued by hfCas13f.1v3-gMECP2 treatment. However, the impaired social behavior of 16-week-old MDS mice could not be rescued.

[0427] In summary, systemic administration of rAAV9-hfCas13f.1v3-gMECP2 via ICV injection efficiently knocked down human MeCP2 in the cortex, striatum, and hippocampus of P1 or adult male MECP2 TG mice. Furthermore, it partially normalized the expression of downstream genes in the cortex. Importantly, administration of rAAV9-hfCas13f.1v3-gMECP2 via ICV injection for 8-10 weeks significantly rescued behavioral impairments in MECP2 TG mice, including motor, anxiety, and social deficits.

[0428] ***

[0429] Various modifications and variations of the products, methods and uses of the present disclosure will be clear to those skilled in the art without departing from the scope and spirit of the present disclosure. Although the present disclosure has been described in conjunction with specific embodiments, it will be understood that further modifications are possible and that the disclosure claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described manner for carrying out the present disclosure that are obvious to those skilled in the art are intended to fall within the scope of the present disclosure. This application is intended to cover any variation, use or adaptation of the present disclosure that generally follows the principles of the present disclosure, and includes such deviations from the present disclosure as are within the known customary practices in the art to which the present disclosure pertains and are applicable to the basic features heretofore shown.

[0430] Exemplary sequences

[0431] Cas13f.1 amino acid sequence, SEQ ID NO: 1

[0432]

[0433] hfCas13f.v2 (Cas13f.1-Y666A+Y677A) amino acid sequence, SEQ ID NO: 2

[0434]

[0435]

[0436] hfCas13f.v2 (Cas13f.1-Y666A+Y677A) coding sequence, SEQ ID NO: 3

[0437] atgaatggcatcgagctgaagaaggaagaagccgccttctacttcaatcaggccgagctgaacctgaaggccattgaggacaacat

[0438] cttcgacaaggagagacggaagacactgctgaacaacccccagatcctggccaagatggagaactttatcttcaatttccgggacgt

[0439] gaccaagaacgccaagggcgaaatcgactgcctgctgctgaagctgagagagctgcggaacttttacagccactacgtgcacaag

[0440] cgggacgtcagagaactgagcaagggcgagaagccgatcctggagaagtactaccagttcgccatcgaatccaccggctctgag

[0441] aacgtgaagctcgaaatcatcgaaaacgacgcctggctggccgacgccggcgtgctgttcttcctgtgcatcttcctgaagaagagc

[0442] caggcaaacaagctgatcagcggcatcagcggcttcaagagaaacgacgacaccggccagcctcggagaaacctgttcacctact

[0443] tctccatccgggagggctacaaggtggtgcccgaaatgcagaagcacttcctgctgttctccctggtgaaccacctgagcaaccagg

[0444] acgattatatcgaaaaggcccaccagccctacgacatcggcgagggcctcttcttccaccggattgccagcaccttcctgaacatctc

[0445] cggaatcctgagaaacatgaagttctacacctatcagagcaagagactggtggagcagagaggcgagctgaagcgggaaaagga

[0446] catcttcgcctgggaagaaccgtttcagggcaattcctactttgagatcaacggccacaagggcgtgattggcgaagacgagctgaa

[0447] ggagctgtgctacgccttcctgatcggcaaccaggacgccaacaaggtggagggccggatcacccagttcctggagaagttcaga

[0448] aacgccaacagcgtgcagcaggtgaaggacgacgagatgctgaagcctgaatatttccccgccaactactttgccgagagcggcg

[0449] tgggccggatcaaggaccgggtgctgaacagactgaacaaggccatcaagagcaacaaggccaagaagggcgagatcatcgcc

[0450] tatgacaagatgagagaagtgatggctttcatcaataactctctgcccgtggacgagaagctgaagcccaaggattacaagagatac

[0451] ctgggcatggtgagattctgggatagagaaaaggacaatatcaagcgcgagttcgaaacgaaggagtggagcaagtatctgccctc

[0452] caacttctggaccgccaagaacctggagagagtgtacggactggcccgggaaaagaacgcagagctgtttaacaagctgaaggc

[0453] cgacgtggagaagatggacgaaagagagctggaaaagtatcagaagatcaacgacgccaaggatctggccaacctgcggcggc

[0454] tggccagcgacttcggagtgaagtgggaggagaaggattgggacgagtactccggccagatcaagaagcagatcacagattccc

[0455] agaagctgaccatcatgaagcagagaatcacagccggcctgaagaagaagcacggcatcgaaaacctgaacctgaggatcacca

[0456] tcgacatcaacaagtccagaaaggccgtgctgaatcggatcgccatccccagaggatttgtgaagcggcacatcctgggctggcag

[0457] gaatccgagaaggtgagcaagaagatcagagaagccgaatgcgagattctgctgagcaaggagtacgaggagctgagcaagca

[0458] gttctttcagagcaaggactacgacaagatgacccgcatcaacggcctgtacgagaagaataagctgatcgccctgatggccgtgta

[0459] tctgatggggcagctgagaatcctgttcaaggagcacaccaagctggacgacatcaccaagaccaccgtggatttcaagatcagcg

[0460] acaaggtgaccgtgaagatccccttctccaacgctccctccctggtgtacaccatgagcagcaaggccgtggacaatatcggcaact

[0461] acggcttcagcaacaaggacaaggataagcccattctgggcaagatcgacgtgatcgagaagcagcggatggagtttatcaagga

[0462] ggtgctgggattcgagaagtacctgtttgacgataagatcatcgacaagagcaagttcgccgacaccgccacccacatcagctttgc

[0463] cgaaatcgtggaagaactggtggagaagggctgggacaaggaccggctgacgaagctgaaggatgcccggaacaaggccctgc

[0464] acggcgagatcctgaccggcaccagcttcgacgagacaaagtccctgatcaacgagctgaagaag

[0465] Amino acid sequence of hfCas13f.v2.5 (Cas13f.1-L641A+Y666A+Y677A), SEQ ID NO:4

[0466]

[0467]

[0468]

[0469] DR sequence, SEQ ID NO:6

[0470]

[0471] gRNA1, SEQ ID NO: 7

[0472]

[0473] gRNA2, SEQ ID NO: 8

[0474]

[0475] gRNA3, SEQ ID NO: 9

[0476]

[0477] gRNA4, SEQ ID NO: 10

[0478]

[0479] gRNA5, SEQ ID NO: 11

[0480]

[0481] gRNA6, SEQ ID NO: 12

[0482]

[0483] gRNA7, SEQ ID NO: 13

[0484]

[0485] gRNA8, SEQ ID NO: 14

[0486]

[0487] gRNA9, SEQ ID NO: 15

[0488]

[0489] gRNA10, SEQ ID NO: 16

[0490]

[0491] Spacer 1 sequence, SEQ ID NO: 17CTGCGCCCCTTGGGGCTGCTCTCCTTGCTT

[0492] Spacer 2 sequence, SEQ ID NO: 18GAAGACTCCTTCACGGCTTTCTTTTTGGCC

[0493] Spacer 3 sequence, SEQ ID NO: 19GGGCTTCACCACTTCCTTGACCTCGATGCT

[0494] Spacer 4 sequence, SEQ ID NO: 20AAAGTCAGCTAACTCTCTCGGTCACGGGCG

[0495] Spacer 5 sequence, SEQ ID NO: 21TTGCGCTCTCCCTCCCCTCGGTGTTTGTAC

[0496] Spacer 6 sequence, SEQ ID NO: 22GTCCACAGGCTCCTCTCTGTTTGGCCTTGG

[0497] Spacer 7 sequence, SEQ ID NO: 23GATTTGGGCTTCTTAGGTGGTTTCTGCTCT

[0498] Spacer 8 sequence, SEQ ID NO: 24GGCTGAGTCTTAGCTGGCTCCTTGGGGCAG

[0499] Spacer 9 sequence, SEQ ID NO: 25GTTACCGTGAAGTCAAAATCATTAGGGTCC

[0500] Spacer 10 sequence, SEQ ID NO: 26GTTACCGTGAAGTCAAAATCATTAGGGTCC

[0501] Target sequence 1, SEQ ID NO: 27

[0502] AAGCAAGGAGAGCAGCCCCAAGGGGCGCAG

[0503] Target sequence 2, SEQ ID NO: 28

[0504] GGCCAAAAAGAAAGCCGTGAAGGAGTCTTC

[0505] Target sequence 3, SEQ ID NO: 29

[0506] AGCATCGAGGTCAAGGAAGTGGTGAAGCCC

[0507] Target sequence 4, SEQ ID NO: 30

[0508] GCCCGTGACCGAGAGAGTTAGCTGACTTT

[0509] Target sequence 5, SEQ ID NO: 31

[0510] GTACAAACACCGAGGGGAGGGAGAGCGCAA

[0511] Target sequence 6, SEQ ID NO: 32

[0512] CCAAGGCCAAACAGAGAGGAGCCTGTGGAC

[0513] Target sequence 7, SEQ ID NO: 33

[0514] AGAGCAGAAACCACCTAAGAAGCCCAAATC

[0515] Target sequence 8, SEQ ID NO: 34

[0516] CTGCCCCAAGGAGCCAGCTAAGACTCAGCC

[0517] Target sequence 9, SEQ ID NO: 35

[0518] GGACCCTAATGATTTTGACTTCACGGTAAC

[0519] Target sequence 10, SEQ ID NO: 36

[0520] ATCAAGAAGCGCAAGACCCGGGAGACGGTCgRNA9&3, SEQ ID NO:37

[0521]

[0522] gRNA9&4, SEQ ID NO:38

[0523]

[0524] gRNA9&5, SEQ ID NO:39

[0525]

[0526] gRNA9&6, SEQ ID NO:40

[0527]

[0528] Non-targeting gRNA, SEQ ID NO:41

[0529]

[0530] Non-targeting spacer sequence, SEQ ID NO:42 GAGACCCAGATCTGCCGGTCTCT

[0531] Non-targeting target sequence, SEQ ID NO:43 AGAGACCGGCAGATCTGGGTCTC

[0532] Cbh promoter, SEQ ID NO:44

[0533] CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCG

[0534] CCCATTGACGTCAATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT

[0535] GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCC

[0536] AAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTGC

[0537] CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTC

[0538] ATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCT

[0539] CCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCA

[0540] GCGATGGGGGCGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGG

[0541] GCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAG

[0542] CGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTA

[0543] TAAAAAGCGAAGCGCGCGGCGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCG

[0544] TGCCCCGCTCCGCCGCCGCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTT

[0545] ACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCT

[0546] GAGCAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAA

[0547] TTACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG

[0548] Enhancer, SEQ ID NO:45

[0549] CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCG

[0550] CCCATTGACGTCAATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT

[0551] GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCC

[0552] AAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTGC

[0553] CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTC

[0554] ATCGCTATTACCATG

[0555] Intron, SEQ ID NO:46

[0556] GGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCCGCTCCgccgccgcctcgcgc

[0557] CGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGAC

[0558] GGCCCTTCTCCTCCGGGCTGTAATTAGCTGAGCAAGAGGTAAGGGTTTAAGGGA

[0559] TGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCTGAAATCA

[0560] CTTTTTTTCAG

[0561] SV40 NLS amino acid sequence, SEQ ID NO:47

[0562] PKKKRKV

[0563] Sequence encoding bGH polyA signal, SEQ ID NO:48CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG

[0564] U6 promoter, SEQ ID NO:49

[0565] GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTA

[0566] GAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATA

[0567] CGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTT

[0568] TAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCT

[0569] TTATATATCTTGTGGAAAGGACGAAACACCG

[0570] CMV promoter, SEQ ID NO:50

[0571] GTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGG

[0572] GGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAA

[0573] ATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGG

[0574] GCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCT

[0575] mCherry amino acid sequence, SEQ ID NO:51

[0576] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTK

[0577] GGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVT

[0578] VTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEI

[0579] KQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYER

[0580] AEGRHSTGGMDELYK

[0581] AAV2 5’ ITR, SEQ ID NO:52

[0582] CTGCGCCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCG

[0583] ACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGC

[0584] CAACTCCATCACTAGGGGTTCCT

[0585] AAV2 3'ITR,SEQ ID NO:53

[0586] AGGACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCCTCGCTCGCTCA

[0587] CTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCT

[0588] CAGTGAGCGAGCGAGCGCGCAG

[0589] Kozak National,SEQ ID NO:54

[0590] gccacc

[0591] AND PROCESS,SEQ ID NO:55

[0592] YPYDVPDYA

[0593] AAV-PHP.eB Specification Process-[hfCas13f.v2]-gRNA 9&3ITR Speciation ITR,SEQ ID NO:56

[0594]

[0595]

[0596]

[0597] AAV-PHP.eB Specification Process-[hfCas13f.v2.5]-gRNA 9&3ITR Speciation ITR,SEQ ID NO:57

[0598]

[0599]

[0600]

[0601] bpSV40 NLS amino acid sequence, SEQ ID NO:58

[0602] KRTADGSEFESPKKKRKV

[0603] WPRE3, SEQ ID NO:59

[0604] AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATG

[0605] TTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATT [[ID=!15]]

[0606] GCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGC

[0607] CACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCT

[0608] GTTGGGCACTGACAATTCCGTGGTGTT

[0609]

[0610] The amino acid sequence of hfCas13f.v3 (Cas13f.1-D160A+D642A+Y666A+Y677A) (hfCas13f), SEQ ID NO: 61

[0611]

[0612]

[0613] The coding sequence of hfCas13f.v3 (Cas13f.1-D160A+D642A+Y666A+Y677A) (hfCas13f), SEQ ID NO: 62

[0614] ATGAATGGCATCGAGCTGAAGAAGGAAGAAGCCGCCTTCTACTTCAATCAGGCC

[0615] GAGCTGAACCTGAAGGCCATTGAGGACAACATCTTCGACAAGGAGAGAAGAAA

[0616] GACACTGCTGAACAACCCCCAGATCCTGGCCAAGATGGAGAACTTTATCTTCAA

[0617] TTTCCGGGACGTGACCAAGAACGCCAAGGGCGAAATCGACTGCCTGCTGCTGAA

[0618] GCTGAGAGAGCTGCGGAACTTTTACAGCCACTACGTGCACAAGCGGGACGTCA

[0619] GAGAACTGAGCAAGGGCGAGAAGCCGATCCTGGAGAAGTACTACCAGTTCGCC

[0620] ATCGAATCCACCGGCTCTGAGAACGTGAAGCTCGAAATCATCGAAAACGACGC

[0621] CTGGCTGGCCGACGCCGGCGTGCTGTTCTTCCTGTGCATCTTCCTGAAGAAGAG

[0622] CCAGGCAAACAAGCTGATCAGCGGCATCAGCGGCTTCAAGAGAAACGACGCCA

[0623] CCGGCCAGCCTCGGAGAAACCTGTTCACCTACTTCTCCATCCGGGAGGGCTACA

[0624] AGGTGGTGCCCGAAATGCAGAAGCACTTCCTGCTGTTCTCCCTGGTGAACCACC

[0625] TGAGCAACCAGGACGATTATATCGAAAAGGCCCACCAGCCCTACGACATCGGC

[0626] GAGGGCCTCTTCTTCCACCGGATTGCCAGCACCTTCCTGAACATCTCCGGAATCC

[0627] TGAGAAACATGAAGTTCTACACCTATCAGAGCAAGAGACTGGTGGAGCAGAGA

[0628] GGCGAGCTGAAGCGGGAAAAGGACATCTTCGCCTGGGAAGAACCGTTTCAGGG

[0629] CAATTCCTACTTTGAGATCAACGGCCACAAGGGCGTGATTGGCGAGGACGAGCT

[0630] GAAGGAGCTGTGCTACGCCTTCCTGATCGGCAACCAGGACGCCAACAAGGTGG

[0631] AGGGCCGGATCACCCAGTTCCTGGAGAAGTTCAGAAACGCCAACAGCGTGCAG

[0632] CAGGTGAAGGACGACGAGATGCTGAAGCCTGAATATTTCCCCGCCAACTACTTT

[0633] GCCGAGAGCGGCGTGGGCCGGATCAAGGACCGGGTGCTGAACAGACTGAACAA

[0634] GGCCATCAAGAGCAACAAGGCCAAGAAGGGCGAGATCATCGCCTATGACAAGA

[0635] TGAGAGAAGTGATGGCTTTCATCAATAACTCTCTGCCCGTGGACGAGAAGCTGA

[0636] AGCCCAAGGATTACAAGAGATACCTGGGCATGGTGAGATTCTGGGATAGAGAA

[0637] AAGGACAATATCAAGCGCGAGTTCGAAACGAAGGAGTGGAGCAAGTATCTGCC

[0638] CTCCAACTTCTGGACCGCCAAGAACCTGGAGAGAGTGTACGGACTGGCCCGGG

[0639] AAAAGAACGCAGAGCTGTTTAACAAGCTGAAGGCCGACGTGGAGAAGATGGAC

[0640] GAAAGAGAGCTGGAAAAGTATCAGAAGATCAACGACGCCAAGGATCTGGCCAA

[0641] CCTGCGGCGGCTGGCCAGCGACTTCGGAGTGAAGTGGGAGGAGAAGGATTGGG

[0642] ACGAGTACTCCGGCCAGATCAAGAAGCAGATCACAGATTCCCAGAAGCTGACC

[0643] ATCATGAAGCAGAGAATCACAGCCGGCCTGAAGAAGAAGCACGGCATCGAAAA

[0644] CCTGAACCTGAGGATCACCATCGACATCAACAAGTCCAGAAAGGCCGTGCTGA

[0645] ATCGGATCGCCATCCCCAGAGGATTTGTGAAGCGGCACATCCTGGGCTGGCAGG

[0646] AATCCGAGAAGGTGAGCAAGAAGATCAGAGAAGCCGAATGCGAGATTCTGCTG

[0647] AGCAAGGAGTACGAGGAGCTGAGCAAGCAGTTCTTTCAGAGCAAGGACTACGA

[0648] CAAGATGACCCGCATCAACGGCCTGTACGAGAAGAATAAGCTGATCGCCCTGAT

[0649] GGCCGTGTATCTGATGGGGCAGCTGAGAATCCTGTTCAAGGAGCACACCAAGCT

[0650] GGCCGACATCACCAAGACCACCGTGGATTTCAAGATCAGCGACAAGGTGACCG

[0651] TGAAGATCCCCTTCTCCAACGCTCCCTCCCTGGTGTACACCATGAGCAGCAAGG

[0652] CCGTGGACAATATCGGCAACTACGGCTTCAGCAACAAGGACAAGGATAAGCCC

[0653] ATTCTGGGCAAGATCGACGTGATCGAGAAGCAGCGGATGGAGTTTATCAAGGA

[0654] GGTGCTGGGATTCGAGAAGTACCTGTTTGACGATAAGATCATCGACAAGAGCAA

[0655] GTTCGCCGACACCGCCACCCACATCAGCTTTGCCGAAATCGTGGAAGAACTGGT

[0656] GGAGAAGGGCTGGGACAAGGACCGGCTGACGAAGCTGAAGGATGCCCGGAAC

[0657] AAGGCCCTGCACGGCGAGATCCTGACCGGCACCAGCTTCGACGAGACAAAGTC

[0658] CCTGATCAACGAGCTGAAGAAG

[0659] mMECP2 promoter, SEQ ID NO:63

[0660] AGCTGAATGGGGTCCGCCTCTTTTCCCTGCCTAAACAGACAGGAACTCCTG

[0661] CCAATTGAGGGCGTCACCGCTAAGGCTCCGCCCCAGCCTGGGCTCCACAAC

[0662] CAATGAAGGGTAATCTCGACAAAGAGCAAGGGGTGGGGCGCGGGCGCGCA

[0663] GGTGCAGCAGCACACAGGCTGGTCGGGAGGGCGGGGCGCGACGTCTGCCG

[0664] TGCGGGGTCCCGGCATCGGTTGCGCGC

[0665] bp SV40 NLS coding sequence 1, SEQ ID NO:64

[0666] AAACGGACAGCCGACGGAAGCGAGTTCGAGTCACCCAAGAAGAAGCGGAAGGT

[0667] G

[0668] bp SV40 NLS coding sequence 2, SEQ ID NO:65

[0669] AAAAGAACCGCCGACGGCAGCGAATTCGAGTCACCCAAGAAGAAGCGGAAGGT

[0670] G

[0671] AAV9 transgenic plasmid - [hfCas13f.v2.5] - gRNA 9&3 ITR to ITR, SEQ ID NO:66

[0672]

[0673]

[0674]

Claims

1. A guide nucleic acid, comprising: (1) a scaffold sequence capable of forming a complex with a nucleic acid programmable RNA nuclease (napRNAn), and (2) A guide sequence capable of hybridizing to a target sequence of human MECP2 mRNA to guide the complex to the human MECP2 mRNA.

2. A system or composition, comprising: (1) a guide nucleic acid or a polynucleotide encoding the guide nucleic acid, wherein the guide nucleic acid comprises: (a) a scaffold sequence capable of forming a complex with a nucleic acid programmable RNA nuclease (napRNAn), and (b) a guide sequence capable of hybridizing to a target sequence of human MECP2 mRNA to guide the complex to the human MECP2 mRNA; and (2) The napRNAn or a polynucleotide encoding the napRNAn.

3. A recombinant adeno-associated virus (rAAV) vector genome, the rAAV vector genome comprising: (a) a first polynucleotide sequence comprising a first sequence encoding a first guide nucleic acid, the first guide nucleic acid comprising: (1) a scaffold sequence capable of forming a complex with a nucleic acid programmable RNA nuclease (napRNAn), and (2) a first guide sequence capable of hybridizing to a first target sequence of human MECP2 mRNA to guide the complex to the human MECP2 mRNA; and (b) a second polynucleotide sequence, wherein the second polynucleotide sequence comprises a sequence encoding the napRNAn, The rAAV vector genome is suitable for encapsulation into recombinant AAV particles.

4. The rAAV vector genome of claim 3, wherein the first polynucleotide sequence further comprises a second sequence encoding a second guide nucleic acid, the second guide nucleic acid comprising: (1) a scaffold sequence capable of forming a complex with napRNAn or the scaffold sequence capable of forming a complex with napRNAn, and (2) a second guide sequence capable of hybridizing to a second target sequence of human MECP2 mRNA to guide the complex to the human MECP2 mRNA.

5. The rAAV vector genome of claim 4, wherein the first polynucleotide sequence further comprises a third sequence encoding a third guide nucleic acid, the third guide nucleic acid comprising: (1) a scaffold sequence capable of forming a complex with napRNAn or the scaffold sequence capable of forming a complex with napRNAn, and (2) capable of hybridizing to a third target sequence of human MECP2 mRNA to guide the complex to the third guide sequence of human MECP2 mRNA.

6. The rAAV vector genome of claim 5, wherein the first polynucleotide sequence further comprises a fourth sequence encoding a fourth guide nucleic acid, the fourth guide nucleic acid comprising: (1) a scaffold sequence capable of forming a complex with napRNAn or the scaffold sequence capable of forming a complex with napRNAn, and (2) capable of hybridizing to a fourth target sequence of human MECP2 mRNA to guide the complex to a fourth guide sequence of human MECP2 mRNA.

7. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide nucleic acid (e.g., the guide nucleic acid, the first guide nucleic acid, the second guide nucleic acid, the third guide nucleic acid, the fourth guide nucleic acid, etc.) is RNA.

8. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein said directing the complex to the human MECP2 mRNA enables the napRNAn to specifically cleave the human MECP2 mRNA.

9. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein specific cleavage of the human MECP2 mRNA results in degradation of the human MECP2 mRNA.

10. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the target sequence (e.g., the target sequence, the first target sequence, the second target sequence, the third target sequence, the fourth target sequence, etc.) is positioned such that the human MECP2 mRNA is specifically cleaved by the napRNAn.

11. The guide nucleic acid, system or composition, or rAAV vector genome of claim 17, wherein the human MECP2 mRNA is as shown in SEQ ID NO:

60.

12. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide nucleic acid comprises the scaffold sequence 5' or 3' of the guide sequence (e.g., the guide sequence, the first guide sequence, the second guide sequence, the third guide sequence, the fourth guide sequence, etc.), and optionally the scaffold sequence 3'.

13. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide nucleic acid comprises, from 5′ to 3′, a guide sequence and a scaffold sequence.

14. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide nucleic acid comprises from 5' to 3' a scaffold sequence, a guide sequence, and a scaffold sequence, wherein the scaffold sequences are the same or different.

15. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide nucleic acid comprises from 5' to 3' a scaffold sequence, a guide sequence, a scaffold sequence and a guide sequence, wherein the scaffold sequences are the same or different, and wherein the guide sequences are the same or different.

16. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide nucleic acid comprises from 5' to 3' a scaffold sequence, a guide sequence, a scaffold sequence, a guide sequence, and a scaffold sequence, wherein the scaffold sequences are the same or different, and wherein the guide sequences are the same or different.

17. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide nucleic acid comprises from 5' to 3' a scaffold sequence, a guide sequence, a scaffold sequence, a guide sequence, a scaffold sequence, and a guide sequence, wherein the scaffold sequences are the same or different, and wherein the guide sequences are the same or different.

18. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the target sequence is at least about 14 nucleotides in length, such as about 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, , 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 or more nucleotides, or a numerical range in length between any two of the foregoing values, for example, from about 16 to about 50 nucleotides in length; optionally, wherein the target sequence is about 30 nucleotides in length.

19. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the target sequence comprises, consists essentially of, or consists of: At least about 14 consecutive nucleotides of the human MECP2 mRNA (e.g., the human MECP2 69, 70 or more consecutive nucleotides of said human MECP2 mRNA, or a numerical range between any two of the preceding values, for example, about 14 to about 50 consecutive nucleotides of said human MECP2 mRNA); optionally, wherein the target sequence comprises, consists essentially of, or consists of: about 30 consecutive nucleotides of said human MECP2 mRNA.

20. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide sequence is at least about 14 nucleotides in length, such as about 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 , 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 or more nucleotides in length, or a numerical range between any two of the aforementioned values ​​in length, for example, about 16 to about 50 nucleotides in length; optionally, wherein the guide sequence is about 30 nucleotides in length.

21. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide sequence is at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% (perfectly) complementary to the target sequence, optionally about 100% (perfectly) complementary; or wherein the guide sequence is at least about 100% complementary to the target sequence; or wherein the guide sequence is at least about 100% complementary to the target sequence; 64, 65, 66, 67, 68, 69, or 70 nucleotides contain no mismatches to the target sequence.

22. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the target sequence comprises, consists essentially of, or consists of: (1) a sequence of any one of SEQ ID NOs: 1-10 or a 5' or 3' truncation thereof with 1, 2, 3, 4, 5 or 6 nucleotides truncated at the 5' or 3' end; or (2) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% sequence identity to any one of SEQ ID NOs: 1-10 or a 5' or 3' truncation thereof with 1, 2, 3, 4, 5 or 6 nucleotides truncated at the 5' or 3' end; or (3) a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotide differences, whether consecutive or not, compared to any one of SEQ ID NOs: 1-10.

23. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide sequence comprises, consists essentially of, or consists of: (1) a sequence of any one of SEQ ID NOs: 17-26 or a 5' or 3' truncation thereof with 1, 2, 3, 4, 5 or 6 nucleotides truncated at the 5' or 3' end; or (2) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% sequence identity to any one of SEQ ID NOs: 17-26 or a 5' or 3' truncation thereof with 1, 2, 3, 4, 5 or 6 nucleotides truncated at the 5' or 3' end; or (3) a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotide differences, whether consecutive or not, compared to any one of SEQ ID NOs: 17-26.

24. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide sequence comprises or is set forth in the sequence of SEQ ID NO: 19 or 25.

25. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the scaffold sequence has a secondary structure substantially identical to the secondary structure of the sequence of SEQ ID NO:

6.

26. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the scaffold sequence comprises, consists essentially of, or consists of: A sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO:6; or a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide differences, whether consecutive or not, compared to the sequence of SEQ ID NO:

6.

27. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide nucleic acid comprises, consists essentially of, or consists of: A sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to the sequence of any one of SEQ ID NOs: 7-16 and 37-40; or a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotide differences, whether consecutive or not, compared to the sequence of any one of SEQ ID NOs: 7-16 and 37-40.

28. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the guide nucleic acid comprises SEQ ID NO:

37.

29. The rAAV vector genome of any of the preceding claims, wherein the first polynucleotide sequence comprises a promoter operably linked to the sequence encoding the guide nucleic acid.

30. The rAAV vector genome of any of the preceding claims, wherein the promoter is a broad-spectrum promoter, a tissue-specific promoter, a cell type-specific promoter, a constitutive promoter, or an inducible promoter; optionally selected from: Cbh promoter, Cba promoter, pol I promoter, pol II promoter, pol III promoter, T7 promoter, U6 promoter, H1 promoter, retrovirus Rous sarcoma virus LTR promoter, cytomegalovirus (CMV) promoter, SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, elongation factor 1α short (EFS) promoter, β-glucuronidase (GUSB) promoter, cytomegalovirus (CMV) immediate early (Ie) enhancer and / or promoter, chicken β-actin (CBA) promoter or its derivatives such as CAG promoter, CB promoter, (human) elongation factor 1α-subunit (EF1α) promoter, ubiquitin C (UBC) promoter, prion promoter, neuron-specific enolase (NSE), neurofilament light chain (NFL) promoter, neurofilament heavy chain (NFH) promoter, Platelet-derived growth factor (PDGF) promoter, platelet-derived growth factor B chain (PDGF-β) promoter, synapsin (Syn) promoter, synapsin 1 (Syn1) promoter, methyl-CpG binding protein 2 (MeCP2) promoter, Ca2+ / calmodulin-dependent protein kinase II (CaMKII) promoter, metabotropic glutamate receptor 2 (mGluR2) promoter, neurofilament light chain (NFL) promoter, neurofilament heavy chain (NFH) promoter, β-globin minigene nβ2 promoter, preproenkephalin (PPE) promoter, enkephalin (Enk) promoter, excitatory amino acid transporter 2 (EAAT2) promoter, glial fibrillary acidic protein (GFAP) promoter, and myelin basic protein (MBP) promoter.

31. The rAAV vector genome of any of the preceding claims, wherein the promoter is a U6 promoter.

32. The rAAV vector genome of any of the preceding claims, wherein the promoter comprises, consists essentially of, or consists of: A sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO:49; or a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide differences, whether contiguous or not, compared to the sequence of SEQ ID NO:

49.

33. The rAAV vector genome of any of the preceding claims, wherein the first polynucleotide sequence comprises, from 5′ to 3′, a promoter of SEQ ID NO: 49 and a sequence encoding a guide nucleic acid of any one of SEQ ID NOs: 7-16 and 37-40.

34. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the napRNAn is a Class 2, Type VI CRISPR-associated protein (Cas13).

35. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the Cas13 is a Cas13a (C2c2), Cas13b (such as, Cas13b1, Cas13b2), Cas13c, Cas13d, Cas13e or Cas13f polypeptide.

36. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the napRNAn comprises, consists essentially of, or consists of: A sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO: 1, 2, 4 or 61, or an N-terminal truncation thereof without the first N-terminal methionine, and retaining at least 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) of the guide sequence-specific RNA cleavage activity of the sequence of SEQ ID NO: 1, 2, 4 or 61.

37. The guide nucleic acid, system or composition, or rAAV vector genome of any of the preceding claims, wherein the sequence encoding the napRNAn comprises, consists essentially of, or consists of: A sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to the sequence of SEQ ID NO: 3, 5 or 62, or a 5' end truncation thereof without the first 5'ATG codon, and wherein the napRNAn encoded by the sequence retains at least 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) of the guide sequence-specific RNA cleavage activity of the sequence of SEQ ID NO: 3, 5 or 62.

38. The rAAV vector genome of any of the preceding claims, wherein the second polynucleotide sequence comprises a promoter operably linked to the sequence encoding the napRNAn.

39. An AAV vector genome as described in any of the preceding claims, wherein the promoter is a broad-spectrum promoter, a tissue-specific promoter, a cell type-specific promoter, a constitutive promoter or an inducible promoter; optionally, wherein the promoter is selected from: Cbh promoter, Cba promoter, pol I promoter, pol II promoter, pol III promoter, T7 promoter, U6 promoter, H1 promoter, retrovirus Rous sarcoma virus LTR promoter, cytomegalovirus (CMV) promoter, SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, elongation factor 1α short (EFS) promoter, β-glucuronidase (GUSB) promoter, cytomegalovirus (CMV) immediate early (Ie) enhancer and / or promoter, chicken β-actin (CBA) promoter or its derivatives such as CAG promoter, CB promoter, (human) elongation factor 1α-subunit (EF1α) promoter, ubiquitin C (UBC) promoter, prion promoter, neuron-specific enolase (NSE), neurofilament light chain (NFL) promoter, neurofilament heavy chain (NFH) promoter, platelet-derived growth factor (PDGF) promoter, platelet-derived growth factor B chain (PDG F-β) promoter, synapsin (Syn) promoter, synapsin 1 (Syn1) promoter, methyl-CpG binding protein 2 (MeCP2) promoter, Ca2+ / calmodulin-dependent protein kinase II (CaMKII) promoter, metabotropic glutamate receptor 2 (mGluR2) promoter, neurofilament light chain (NFL) promoter, neurofilament heavy chain (NFH) promoter, β-globin minigene nβ2 promoter, preproenkephalin (PPE) promoter, enkephalin (Enk) promoter, excitatory amino acid transporter 2 (EAAT2) promoter, glial fibrillary acidic protein (GFAP) promoter, myelin basic protein (MBP) promoter, HTT promoter, GRK1 promoter, CRX promoter, NRL promoter, MECP2 promoter, mMECP2 promoter, hMECP2 promoter and RCVRN promoter.

40. The rAAV vector genome of any of the preceding claims, wherein the promoter is a neural cell (eg, neuron) specific promoter, such as the MECP2 promoter.

41. The rAAV vector genome of any of the preceding claims, wherein the promoter is a Cbh promoter, a CMV promoter, an mMECP2 promoter, or an hMECP2 promoter.

42. The rAAV vector genome of any of the preceding claims, wherein the second polynucleotide sequence comprises a Kozak sequence 5' to the sequence encoding the napRNAn.

43. The rAAV vector genome of any of the preceding claims, wherein the second polynucleotide sequence comprises a sequence encoding an NLS 5' and / or 3' to the sequence encoding the napRNAn.

44. The rAAV vector genome of any of the preceding claims, wherein the second polynucleotide sequence comprises a sequence encoding a first NLS 5' to the sequence encoding the napRNAn and a second sequence encoding a second NLS 3' to the sequence encoding the napRNAn.

45. The rAAV vector genome of any of the preceding claims, wherein the NLS, the first NLS and / or the second NLS is a SV40 NLS, a bpSV40 NLS or a nucleoplasmin NLS (npNLS).

46. ​​The rAAV vector genome of any of the preceding claims, wherein the second polynucleotide sequence comprises a WPRE sequence downstream of the sequence encoding the napRNAn.

47. The rAAV vector genome of any of the preceding claims, wherein the WPRE sequence is selected from the group consisting of a woodchuck hepatitis virus (WHP) post-transcriptional regulatory element (WPRE), WPRE3 (shortened WPRE), and functional variants thereof (e.g., functional truncations).

48. The rAAV vector genome of any of the preceding claims, wherein the second polynucleotide sequence comprises a sequence encoding a polyadenylation (polyA) signal downstream of the sequence encoding the napRNAn.

49. The rAAV vector genome of any of the preceding claims, wherein the second polynucleotide sequence comprises a WPRE sequence downstream of the sequence encoding the napRNAn, followed by a sequence encoding a polyadenylation (polyA) signal.

50. The rAAV vector genome of any of the preceding claims, wherein the polyA signal is selected from the group consisting of a bovine growth hormone polyadenylation (bGH polyA) signal, a small polyA (SPA) signal, a human growth hormone polyadenylation (hGH polyA) signal, an SV40 polyA (SV40 polyA) signal, a rabbit beta globin polyA (rBG polyA) signal, and functional variants thereof (e.g., functional truncations).

51. The rAAV vector genome of any of the preceding claims, wherein the polyA signal is a bGH polyA signal.

52. The rAAV vector genome of any of the preceding claims, wherein the second polynucleotide sequence comprises from 5' to 3' the promoter, the Kozak sequence, the first sequence encoding the first NLS, the sequence encoding the napRNAn, the second sequence encoding the second NLS, the WPRE sequence, and the sequence encoding the polyA signal.

53. The rAAV vector genome of any of the preceding claims, wherein the promoter comprises, consists essentially of, or consists of: A sequence encoding a polypeptide having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to the sequence of SEQ ID NO:47, 58 or 64; or a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotide differences, whether contiguous or not, compared to the sequence of SEQ ID NO:47, 58 or 64.

54. The rAAV vector genome of any of the preceding claims, wherein the Kozak sequence comprises, consists essentially of, or consists of: A sequence encoding a polypeptide having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO:54; or a sequence having at most 1, 2, 3, or 4 nucleotide differences, whether contiguous or not, compared to the sequence of SEQ ID NO:

54.

55. The rAAV vector genome of any of the preceding claims, wherein the NLS, the first NLS, and / or the second NLS comprises, consists essentially of, or consists of: A sequence encoding a polypeptide having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to the sequence of SEQ ID NO: 47 or 58; or a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid differences, whether contiguous or not, compared to the sequence of SEQ ID NO: 47 or 58.

56. The rAAV vector genome of any of the preceding claims, wherein the sequence encoding the NLS, the first sequence encoding the first NLS, and / or the second sequence encoding the second NLS comprises, consists essentially of, or consists of: A sequence encoding a polypeptide having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to the sequence of SEQ ID NO: 64 or 65; or a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid differences, whether contiguous or not, compared to the sequence of SEQ ID NO: 64 or 65.

57. The rAAV vector genome of any of the preceding claims, wherein the sequence encoding the polyA signal comprises, consists essentially of, or consists of: A sequence encoding a polypeptide having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO:48; or a sequence having at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide differences, whether contiguous or not, compared to the sequence of SEQ ID NO:

48.

58. The rAAV vector genome of any of the preceding claims, wherein the second polynucleotide sequence comprises from 5' to 3' the promoter of SEQ ID NO:63, the Kozak sequence of SEQ ID NO:54, the first sequence encoding the first NLS of SEQ ID NO:64, a 5' end truncation of the sequence encoding the napRNAn of SEQ ID NO:62 without the first 5'ATG codon, the second sequence encoding the second NLS of SEQ ID NO:65, the WPRE sequence of SEQ ID NO:59, and the sequence encoding the polyA signal of SEQ ID NO:

48.

59. The rAAV vector genome of any of the preceding claims, wherein the rAAV vector genome comprises a 5' inverted terminal repeat (ITR) sequence and a 3' ITR sequence.

60. The rAAV vector genome of any of the preceding claims, wherein the 5' ITR sequence and the 3' ITR sequence are both wild-type ITR sequences from: a member of the evolutionary branch to which any one of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV-DJ, AAV PHP.eB, or AAV1-AAV13 belongs, or a functional variant thereof (e.g., a functional truncation).

61. The rAAV vector genome of any of the preceding claims, wherein the 5' ITR sequence comprises, consists essentially of, or consists of: A sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO:

52.

62. The rAAV vector genome of any of the preceding claims, wherein the 3' ITR sequence comprises, consists essentially of, or consists of: A sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the sequence of SEQ ID NO:

53.

63. The rAAV vector genome of any of the preceding claims, wherein the rAAV vector genome comprises the first polynucleotide sequence and the second polynucleotide sequence from 5' to 3'.

64. The rAAV vector genome of any of the preceding claims, wherein the rAAV vector genome comprises the second polynucleotide sequence and the first polynucleotide sequence from 5' to 3'.

65. The rAAV vector genome of any of the preceding claims, wherein the rAAV vector genome comprises, consists essentially of, or consists of: A sequence having at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%) sequence identity to the sequence of SEQ ID NO:56, 57 or 66; optionally, the rAAV vector genome comprises the sequence of SEQ ID NO:

66.

66. A recombinant AAV (rAAV) particle comprising the rAAV vector genome of any of the preceding claims.

67. The rAAV particle of any of the preceding claims, wherein the rAAV particle comprises a capsid of a serotype of AAV1, AAV2, AAV3A, AAV3B, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV-DJ, or a member of an evolutionary branch to which any one of AAV.PHP.eB, AAV1-AAV13 belongs, or a functional variant thereof (e.g., a functional truncation), which encapsulates the rAAV vector genome.

68. The rAAV particle of any of the preceding claims, wherein the capsid is of the serotype AAV9 or AAV.PHP.eB or a variant or mutant thereof.

69. A pharmaceutical composition comprising the system or composition of any of the preceding claims or the rAAV particle of any of the preceding claims and a pharmaceutically acceptable excipient.

70. The pharmaceutical composition of any of the preceding claims, wherein the pharmaceutical composition comprises the rAAV particles at a concentration selected from about 1×10 10 vg / mL, 2×10 10 vg / mL, 3×10 10 vg / mL, 4×10 10 vg / mL, 5×10 10 vg / mL, 6×10 10 vg / mL, 7×10 10 vg / mL, 8×10 10 vg / mL, 9×10 10 vg / mL, 1×10 11 vg / mL, 2×10 11 vg / mL, 3×10 11 vg / mL, 4×10 11 vg / mL, 5×10 11 vg / mL, 6×10 11 vg / mL, 7×10 11 vg / mL, 8×10 11 vg / mL, 9×10 11 vg / mL, 1×10 12 vg / mL, 2×10 12 vg / mL, 3×10 12 vg / mL, 4×10 12 vg / mL, 5×10 12 vg / mL, 6×10 12 vg / mL, 7×10 12 vg / mL, 8×10 12 vg / mL, 9×10 12 vg / mL, 1×10 13 vg / mL, or a concentration in a numerical range between any two of the foregoing values, such as about 9×10 10 vg / mL to about 8×10 11 The concentration of vg / mL.

71. A pharmaceutical composition as described in any one of the preceding claims, wherein the pharmaceutical composition is an injectable solution.

72. pharmaceutical composition as described in any one of the preceding claims, the volume of wherein the injection is selected from about 1 microliter, 10 microliters, 50 microliters, 100 microliters, 150 microliters, 200 microliters, 250 microliters, 300 microliters, 350 microliters, 400 microliters, 450 microliters, 500 microliters, 550 microliters, 600 microliters, 650 microliters, 700 microliters, 750 microliters, 800 microliters, 850 microliters, 900 microliters, 950 microliters, 1000 microliters, and the volume in the numerical range between any two of the aforementioned values, for example a concentration of about 10 microliters to about 750 microliters.

73. A method for preventing or treating a disease associated with human MECP2 mRNA in a subject in need thereof, the method comprising administering to the subject the system or composition of any of the preceding claims, the rAAV particles of any of the preceding claims, or the pharmaceutical composition of any of the preceding claims, wherein the napRNAn modifies the human MECP2 mRNA, and wherein the modification of the human MECP2 mRNA treats the disease.

74. The method of any of the preceding claims, wherein the disease is MECP2 Duplication Syndrome (MDS).

75. The method of any of the preceding claims, wherein the administering comprises topical administration.

76. The method of any of the preceding claims, wherein the administration comprises intracerebroventricular administration (e.g., intracerebroventricular injection).

77. The method of any of the preceding claims, wherein the administration comprises systemic administration.

78. The method of any of the preceding claims, wherein the subject is a human.

79. The method of any of the preceding claims, wherein the level of human MECP2 mRNA in the subject is reduced by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or more compared to the level of human MECP2 mRNA in the subject before the administration.

80. The method of any of the preceding claims, wherein the level of human MECP2 protein in the subject is at most about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, or about 85% compared to the level of human UBE3A protein in a person or population not suffering from the disease.

81. A cell or its progeny, comprising the guide nucleic acid of any of the preceding claims, the system or composition of any of the preceding claims, the rAAV vector genome of any of the preceding claims, or the rAAV particle of any of the preceding claims.

82. A cell or progeny thereof as described in any one of the preceding claims, wherein the cell is a eukaryotic cell.

83. A cell or progeny thereof as described in any one of the preceding claims, wherein the cell is a human cell.

84. A cell or progeny thereof as described in any of the preceding claims, wherein the cell is a human neural cell (e.g., a neuron).

85. A kit comprising the guide nucleic acid of any of the preceding claims, the system or composition of any of the preceding claims, the rAAV vector genome of any of the preceding claims, the rAAV particle of any of the preceding claims, or the cell or progeny thereof of any of the preceding claims.

Citation Information

Patent Citations

  • High-efficiency wild-type-free AAV helper functions

    US6001650A

  • Compositions and methods for gene editing

    WO2018002719A1

Cited By

  • Construction method and application of hMECP2 gene humanized mouse model

    CN121718575A